Document:

EX-10.15

 Exhibit 10.15 
  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

EXECUTION COPY 
 CONFIDENTIAL 

 
 APG1252 License Agreement 

This APG1252 License Agreement (the “Agreement”) effective as of the 2nd
day of Feburary, 2016, (the “Signing Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road,
Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Each of Ascentage and Unity shall be a
“Party,” and both the “Parties.” 
 BACKGROUND 

A. Unity and Ascentage entered into that certain Compound Library and Option Agreement of even date herewith (the “Library
Agreement”), pursuant to which Ascentage has granted to Unity the right to screen Ascentage’s existing collection of BCL-2/BCL-xL inhibitor compounds as
well as any additional BCL-2/BCL-xL inhibitor compounds discovered by Ascentage during the term of the Library Agreement, in each case to identify compounds with
potential utility in the treatment of age-related conditions other than Oncology Indications; and 

B. Ascentage has begun developing a BCL-2/BCL-xL inhibitor
known as APG-1252 (as further defined below) and owns or controls certain patents, know-how and other intellectual property relating to
APG-1252. 
 C. Unity desires to acquire from Ascentage a license under the Licensed Intellectual
Property to develop APG-1252 in the Field and Territory (each as defined below), and Ascentage is willing to grant Unity such license on the terms and conditions herein, all as set forth below. 

NOW, THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and between the
Parties as follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1 The
following terms have the meanings set forth in the Library Agreement: 
 Affiliate 

Ascentage Intellectual Property 

Collaboration Period 
 Compounds

 Compound License Agreement(s) 

Greater China 
 IND 

Oncology Indications 
 Patents

 Technology 
 Third Party

 Unity Bcl-2 [***] Product 

 EXECUTION COPY 

CONFIDENTIAL 
  

 1.2 “APG-1252” means the chemical
compound with the structure identified in Schedule 1.2, [***]. 
 1.3 “APG-1252 Work-a-Like Product” means a Licensed Product under a Compound License Agreement, which product is [***] and is subject to the milestones and royalties described as
[***] in Sections 5.2 (Development/Sales Milestones) and 5.3 (Royalties) of the Form of Compound License Agreement attached as Exhibit 3.3.2(a) of the Library Agreement. 

1.4 “Fair Market Value” means with respect to a share of Unity common stock, the average price that Unity common stock is
publicly trading at for [***] ([***]) days prior to the date in question, or, if the security is not publicly traded, the value of such stock as determined in good faith by Unity’s board of directors in reliance upon Unity’s most recent
IRC Section 409A independent valuation of Unity’s common stock that it used for the purposes of granting stock options to its employees. 

1.5 “Control” and its correlative terms, “Controlled” or “Controls” shall mean, with respect
to any Patent or item of Technology, that a Party or one of its Affiliates owns or possesses rights to such Patent or item of Technology sufficient to grant the access, license or sublicense contemplated in this Agreement without violating the terms
of any agreement or other arrangement with any Third Party. 
 1.6 “Cover” and its correlative terms,
“Covers”, “Covered” or “Covering” means (a) with respect to an issued patent, that, in the absence of a license, the use, offer for sale, sale, importation or manufacture of the product in
question would infringe one or more claims of such patent or (b) with respect to a pending patent application, that, in the absence of a license, the use, offer for sale, sale, importation or manufacture of the product in question would
infringe one or more claims of such patent application, should such claims issue as published. 
 1.7 “Effective Date” shall
mean the date on which the Second Amendment takes effect. 
 1.8 “Enabling IP” means Patents and/or Technology of a Third
Party that Covers or relates to a Royalty-bearing Product and is necessary or useful for the research, development, manufacture, use, sale or import of Royalty-bearing Products, including Patents directed to the composition and manufacture of
Licensed Compound, but excluding Patents related to formulation and therapeutic methods. 
 1.9 “EMA” means the European
Medicines Agency and any successor agency. 
 1.10 “Existing Agreements” means (a) that certain Exclusive License
Agreement between Unity and the Mayo Foundation for Medical Education and Research originally entered into by the parties effective June 28th, 2013; (b) that certain Exclusive License Agreement between Unity and the Buck Institute for
Research on Aging originally entered into by the parties effective February 3rd, 2014; and (c) that certain Exclusive License Agreement between Unity and the Board of Trustees of the University of Arkansas originally entered into by the
parties effective April 28th, 2015. 
 1.11 “FDA” means the United States Food and Drug Administration and any
successor agency. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 1.12 “Field” means the prophylaxis and treatment of, and palliation of
symptoms associated with, indications other than Oncology Indications. 
 1.13 “Generic Product” means a product which
(a) contains as its active pharmaceutical ingredient a compound that is (or is substantially the same as) the Licensed Compound or the active pharmaceutical contained in a Unity Bcl-2 [***] Product, and
(b) has been placed on the market pursuant to a validly granted marketing authorization. 
 1.14 “Licensed Compound”
means APG-1252. 
 1.15 “Licensed Intellectual Property” means the Licensed Patents
and Licensed Technology. 
 1.16 “Licensed Patents” means Patents owned or Controlled by Ascentage or its Affiliates during
the Term, in each case to the extent Covering the Licensed Compound, a Licensed Product or a Unity Bcl-2 [***] Product. 

1.17 “Licensed Product” means a pharmaceutical product containing the Licensed Compound (either alone or with other active
pharmaceutical ingredients), in all forms, presentations, formulation and dosage forms. 
 1.18 “Licensed Technology” means
Technology owned or Controlled by Ascentage or its Affiliates during the Term, in each case to the extent such Technology is necessary or reasonably useful for the development, manufacture or commercialization of the Licensed Compound, a Licensed
Product or a Unity Bcl-2 [***] Product. 
 1.19 “Marketing Approval Application” or
“MAA” means a New Drug Application (or its equivalent), as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any
country. 
 1.20 “Net Sales” means the gross amount invoiced to non-Affiliate Third
Parties on sales of Royalty-bearing Products by Unity or its Affiliates or Third Party Sublicensees, less the actual amounts incurred, allowed, or paid for the following items (if not previously deducted from the amount invoiced and provided that
such deductions are calculated in accordance with generally accepted accounting principles of the United States of America (“GAAP”) on a consistent basis): (a) trade, cash, and quantity discounts; (b) amounts for claims,
allowances or credits for returns, rejections or recalls; (c) freight, shipping and insurance charges allocable to such Royalty-bearing Products; (d) sales taxes, duties and other governmental charges (including value added tax) on
particular sales, but excluding what is commonly known as income taxes; (e) government mandated rebates; (f) contracted rebates; and (g) a provision for uncollectible accounts; in each case as determined from books and records of the
selling party maintained in accordance with GAAP, as consistently applied by such selling party. In the event that Unity grants a sublicense to a Third Party Sublicensee hereunder, and receives payments based upon such Third Party Sublicensee’s
sales of Royalty-bearing Product, Unity may, with Ascentage’s consent, which consent shall not be unreasonably withheld or delayed, substitute the definition of “Net Sales,” used by such Third Party Sublicensee to calculate its
payments to Unity in place of the foregoing definition of “Net Sales” for purposes of calculating royalties payable to Ascentage on such Third Party Sublicensee’s sales. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 1.21 “Phase I Clinical Trial” means a human clinical trial, the principal
purpose of which is preliminary determination of safety of a drug in healthy individuals or patients, that would satisfy the requirements of 21 C.F.R. §312.21(a). 

1.22 “Phase II Clinical Trial” means a clinical trial of a drug conducted on a limited number of patients for the purpose of
preliminary evaluation of clinical efficacy and safety of such drug, and/or to obtain an indication of the dosage regimen required, in each case that would satisfy the requirements of 21 C.F.R. 312.21(b). 

1.23 “Phase III Clinical Trial” means a pivotal human clinical trial intended to gather additional information regarding the
safety and efficacy of the drug in patients with the disease being studied, which clinical study is designed to be of a size and statistical power sufficient to support the filing of an MAA and that would satisfy the requirements of 21 C.F.R.
312.21(c). 
 1.24 “Royalty-bearing Product” means a Licensed Product or a Unity
Bcl-2 [***] Product. 
 1.25 “Royalty-bearing Product-Specific Patents” means those
Licensed Patents that [***] the Licensed Compound, a Licensed Product or a Unity Bcl-2 [***] Product and [***]. 

1.26 “Territory” means the entire world excluding Greater China. 

1.27 “Third Party Sublicensee” means any Third Party to which Unity licenses the right to commercialize any Royalty-bearing
Product. For the avoidance of doubt, “Third Party Sublicensee” shall not include Third Party distributors, service providers, vendors and suppliers that do not have the right to market or promote the Royalty-bearing Product. 

1.28 “UM License Agreement” means that certain license agreement entered into by Ascentage and the Regents of the University
of Michigan (“UM”) effective as of December 1, 2010, as amended by all amendments to such license agreement existing as of the Effective Date. 

1.29 “Unity Bcl-2 [***] Product” means any [***] product for [***], wherein the [***],
and in each case that (a) is developed by Unity during the Collaboration Period, (b) is not an APG-1252 Work-a-Like
Product, and (c) for which an IND is filed prior to the later of the [***] anniversary of the Effective Date or the [***] anniversary of the expiration or termination of the Library Agreement. Notwithstanding anything to the contrary in this
Agreement, any compound that was designed ([***]) or [***] synthesized [***] shall not be considered a Unity Bcl-2 [***] Product without Unity’s express written consent. [***] In addition, Unity agrees
that upon request it will [***]. 
 1.30 “Valid Claim” means a claim contained in an issued Patent within the Licensed
Patents in any country that (a) has not expired; (b) has not been disclaimed; (c) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (d) has not been revoked, held invalid, or otherwise
declared unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over such claim in such country from which no further appeal has or may be taken. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 ARTICLE 2 

LICENSES 
 2.1
Licenses. 
 2.1.1 Development Licenses. Subject to the terms and conditions of this Agreement, Ascentage hereby grants to
Unity a royalty-free, exclusive license in the Field and Territory, with the right to grant sublicenses as provided in Section 2.2, under the Licensed Intellectual Property to (a) research, develop and seek and obtain marketing approval
for the Licensed Compound and Licensed Products using Licensed Compound and/or Licensed Products supplied by or on behalf of Ascentage and (b) research, make, develop and seek and obtain marketing approval for Unity Bcl-2 [***] Products; in each case solely in the Field and Territory, and to have any of the foregoing performed on its behalf by a Third Party; and 

2.1.2 Commercialization Licenses. Subject to the terms and conditions of this Agreement, Ascentage hereby grants to Unity a
royalty-bearing, exclusive license in the Field and Territory, with the right to grant sublicenses as provided in Section 2.2, under the Licensed Intellectual Property: (a) to use the Licensed Compound supplied by or on behalf of Ascentage
to make or have made the Licensed Products; (b) to use, offer for sale, sell, import, export, market, promote and distribute Licensed Compound and Licensed Products, and (c) to make, use, offer for sale, sell, import, export, market,
promote and distribute Unity Bcl-2 [***] Products; in each case, solely for use in the Field and Territory, and to have any of the foregoing performed on its behalf by a Third Party. It is understood and
agreed that the licenses set forth in this Section 2.1.2 exclude the right to make or have made the Licensed Compound. 
 2.2
Sublicenses. Unity may grant and authorize sublicenses within the scope of the license granted to Unity pursuant to this Agreement, provided that for clarity, Unity shall remain responsible for all milestone and other payments due to
Ascentage under this Agreement based on the activities of Unity’s sublicensees. 
 2.3 Third Party Intellectual Property. If
after the Effective Date, Ascentage acquires or licenses from a Third Party subject matter that would fall within the Licensed Intellectual Property (“Third Party Intellectual Property”) that is subject to any payment obligation to
the Third Party, then Ascentage shall so notify Unity and Unity shall inform Ascentage if it wishes such subject matter to be included within the Licensed Intellectual Property. If Unity notifies Ascentage that it does wish such subject matter to be
so included, the rights granted to Unity hereunder with respect to such Third Party Intellectual Property shall be subject to Unity promptly reimbursing Ascentage for [***] and Unity shall reimburse Ascentage for [***]. Upon request by Unity,
Ascentage shall disclose to Unity a written description of such payment obligations. Notwithstanding the foregoing, Unity shall have the right to treat amounts paid to Ascentage as reimbursements for payments for Enabling IP for purposes of
Section 5.5. 
 2.4 No Implied Licenses. Nothing herein shall be construed as granting Unity, by implication, estoppel or
otherwise, any license or other right (a) to any intellectual property of Ascentage other than the Licensed Intellectual Property (b) to commercialize Licensed Products outside of the Field and Territory (c) not relating to the
Licensed Compound, Licensed Products and Unity Bcl-2 [***] Products or (d) any right or license other than those expressly granted herein. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 2.5 [***]. 

2.6 Exclusivity/[***]. 

2.6.1 Exclusivity. 
 (a)
No Development or Commercialization of Licensed Compound in the Field. Ascentage hereby covenants that except as expressly permitted under any future agreement that the Parties may enter into pursuant to Article 8 below pertaining to the
China JVCO, Ascentage shall not: (a) research, develop, use or commercialize, and shall not authorize any Affiliate or other Third Party to research, develop, use or commercialize, the Licensed Compound (or any Licensed Product) in the Field,
and (b) manufacture, or authorize any Third Party to manufacture, the Licensed Compound or any Licensed Product for use in the Field, other than for supply to Unity in accordance with the terms of the Supply Agreement to be negotiated pursuant
to Article 4 below. 
 (b) No Development or Commercialization of Licensed Compounds. Ascentage hereby covenants that except as
expressly permitted under any future agreement that the Parties may enter into pursuant to Article 8 below pertaining to the China JVCO, Ascentage shall not research, develop, manufacture, use or commercialize, and shall not authorize any Affiliate
or other Third Party to research, develop, manufacture, use or commercialize, any Unity Bcl-2 [***] Products. 

(c) Notwithstanding anything to the contrary, Ascentage shall be permitted to develop any products containing the Licensed Compound for
Oncology Indications independently. 
 2.6.2 [***] Licensed Products. Within [***] of the effective date of the Library Agreement the
Parties will [***] to [***]. The [***] is [***]. In addition, the [***] to [***]. Ascentage will appoint [***] and Unity will appoint [***] to [***].  

2.7 [***]. The Parties agree that within [***] of the Effective Date of this Agreement they will put in place a procedure pursuant to which
[***] shall [***] that [***] to [***]. 
 ARTICLE 3 

DUE DILIGENCE 
 3.1
General. Unity shall use commercially reasonable efforts to develop and obtain marketing approval for at least one Royalty Product or APG-1252 Work-a-Like Product (collectively, “[***] Product”), and thereafter shall use commercially reasonable efforts to launch and commercialize each such [***] Product and to fulfil the market
demand therefor. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 3.2 Diligence Milestones. Without limiting the it’s general diligence obligations
under Section 3.1 above, Unity agrees that it shall achieve the following diligence milestones with respect to a [***] Product by the deadlines specified below: 
  

			
	 Milestone
	  	 Time Period

	1. [***]	  	Within [***] ([***]) [***] of the Effective Date
	2. [***]	  	Within [***] ([***]) [***] of the Effective Date
	3. [***]	  	Within [***] ([***]) [***] of the Effective Date
	4. [***]	  	Within [***] ([***]) [***] of the Effective Date

 If Unity is unable to meet [***], as applicable, by the specified deadline, Unity shall none-the-less be deemed to be in compliance with its diligence obligations hereunder so long as it [***]. 

ARTICLE 4 
 MANUFACTURE
AND SUPPLY 
 4.1 Within [***] of the effective date of the Library Agreement, the Parties will negotiate and agree upon the terms and
conditions pursuant to which Ascentage (itself or through one or more Third Party contract manufacturers) shall manufacture and supply Unity, its Affiliates and their Third Party Sublicensees with (a) Licensed Product for clinical use, and
(b) Licensed Compound for commercial use (the “Supply Agreement”). Ascentage will appoint [***] and Unity will appoint [***] to negotiate such Supply Agreement on their respective behalf. For clarity it is acknowledged that
[***]. 
 ARTICLE 5 

PAYMENTS 
 5.1 Equity
Grants. 
 5.1.1 Upfront Fee. As partial consideration for the rights and licenses granted to Unity under this Agreement, Unity
shall issue to Ascentage, subject to Ascentage’s execution and delivery to Unity of a Stock Issuance Agreement in substantially the form attached hereto as Schedule 5.1 (such form of agreement, the “Stock
Agreement”), One Million Five Hundred Seventy Three Thousand Three Hundred Forty (1,573,340) shares of Unity common stock; such shares to be issued to Ascentage within [***] ([***]) days of the Effective Date. 

5.1.2 [***]. Upon the [***], Unity shall issue to Ascentage Three Hundred Ninety Three Thousand Three Hundred Thirty Five (393,335)
shares of Unity common stock; such shares to be issued to Ascentage pursuant to the Stock Agreement within [***] ([***]) days of date that [***] occurs. For clarity, [***]. 

5.1.3 [***]. Upon the [***], Unity shall issue to Ascentage the following number of shares of Unity common stock based on how long after
the Effective Date such [***]; such shares to be issued to Ascentage pursuant to the Stock Agreement within [***] ([***]) days of date that such [***] occurs: 

(a) [***] ([***]) shares of Unity common stock if such [***] occurs within [***] ([***]) [***] of the Effective Date. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 (b) [***] ([***]) shares of Unity common stock if such [***] occurs more than [***] ([***])
[***] after the Effective Date but less than [***] ([***]) [***] after the Effective Date. 
 (c) [***] ([***]) shares of Unity common stock
if such [***] occurs more than [***] ([***]) [***] after the Effective Date. 
 5.1.4 Equity
Cap.    Notwithstanding anything in the contrary in this Agreement, the Library Agreement or any Compound License Agreement(s), the maximum cumulative aggregate number of shares of Unity common stock that Ascentage is
eligible to receive under Sections 6.1 and 6.2 of the Library Agreement, Section 5.1 of any Compound License Agreement(s) and this Section 5.1 is: 

(a) [***] ([***]) shares of Unity common stock if only one Licensed Product is developed; and 

(b) Three Million Nine Hundred Thirty Three Thousand Three Hundred and Fifty (3,933,350) shares of Unity common stock if two or more Licensed
Products is developed. 
 5.2 Development/Sales Milestones. In partial consideration of the rights and licenses granted herein to
Unity, Unity shall pay Ascentage the following milestone payments: 
 5.2.1 Licensed Products. Within [***] ([***]) days after the
first achievement by Unity (or any of its Affiliates or Third Party Sublicensees) of each of the following milestones with respect to a Licensed Product, Unity shall pay Ascentage the corresponding milestone payment set forth below, in accordance
with the payment provisions of Article 6 below: 
  

					
	 Milestone Event
	  	Milestone Payment	 
	 1. [***]:
	  	$	[***]	 
	 2. [***]:
	  	$	[***]	 
	 3. [***]:
	  	$	[***]	 
	 4. [***]
	  	$	[***]	 
	 5. [***]
	  	$	[***]	 
		  	  
	  
	 
	 Total per Licensed Product
	  	$	[***]	 
		  	  
	  
	 

 5.2.2 Unity Bcl-2 [***] Products. Within [***] ([***]) days
after the first achievement by Unity (or any of its Affiliates or Third Party Sublicensees) of each of the following milestones with respect to a Unity Bcl-2 [***] Product, Unity shall pay Ascentage the
corresponding milestone payment set forth below, in accordance with the payment provisions of Article 6 below: 
  

					
	 Milestone Event
	  	Milestone Payment	 
	 1. [***]:
	  	$	[***]	 
	 2. [***]:
	  	$	[***]	 
	 3. [***]:
	  	$	[***]	 
	 4. [***]
	  	$	[***]	 
	 5. [***]
	  	$	[***]	 
		  	  
	  
	 
	 Total per Unity Bcl-2 [***] Product
	  	$	[***]	 
		  	  
	  
	 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 5.2.3 Certain Additional Terms. 

(a) For clarity, all forms, presentations, formulation and dosage forms of a Licensed Product or Unity
Bcl-2 [***] Product shall be considered one and the same Licensed Product or Unity Bcl-2 [***] Product (as applicable) for purposes of this Section 5.2. 

(b) If Unity begins development of one Licensed Product or Unity Bcl-2 [***] Product and a milestone
payment is made under this Section 5.2, and then Unity terminates development of such product and begins development of a second Licensed Product or Unity Bcl-2 [***] Product, the milestone which was
already paid under this Section 5.2 for the abandoned product will not be repeated, but the remaining milestone payments hereunder will be due as the second Licensed Product or Unity Bcl-2 [***] Product
(as applicable) advances; 
 (c) In its sole discretion, Unity may elect in lieu of the payment of the milestone payments owing to Ascentage
under this Section 5.2, to grant to Ascentage that number of shares of Unity common stock of equivalent value (based on the Fair Market Value of such Unity common stock at the time of such grant). 

5.3 Royalties. In partial consideration of the licenses granted herein to Unity, Unity shall pay to Ascentage a running royalty equal to
the percentage set forth below on the Net Sales of each Royalty-bearing Product based on whether such Royalty-bearing Product is a Licensed Product or Unity Bcl-2 [***] Product, subject to any adjustments set
forth in Sections 5.5 and 5.6, and in accordance with the payment provisions of Article 6 below. 
 5.3.1 Licensed Products. 

 

					
	 Annual Net Sales of Licensed Product
	  	Applicable Royalty Rate	 
	 Portion of worldwide annual Net Sales of the Licensed Product less than or equal to [***] Dollars
(US$[***])
	  	 	[***]	% 
	 Portion of worldwide annual Net Sales of the Licensed Product over [***] Dollars
(US$[***])
	  	 	[***]	% 

 5.3.2 Unity Bcl-2 [***] Products. 

 

					
	 Annual Net Sales of Licensed Product
	  	Applicable Royalty Rate	 
	 Portion of worldwide annual Net Sales of the Licensed Product less than or equal to [***] Dollars
(US$[***])
	  	 	[***]	% 
	 Portion of worldwide annual Net Sales of the Licensed Product over [***] Dollars
(US$[***])
	  	 	[***]	% 

 5.4 Royalty Term. Unity’s obligation to pay royalties on Net Sales of Royalty-bearing Products
under this Agreement shall continue on a country-by-country and Royalty-bearing
Product-by-Royalty-bearing Product basis until the later of (a) abandonment or expiration of the last Valid Claim that claims the [***] of the Licensed Compound (or
the [***] contained in the Unity Bcl-2 [***] Product) in such country, (b) the date of expiry of any applicable regulatory, pediatric, orphan drug or data exclusivity obtained for such Royalty-bearing
Product in such country, or (c) ten (10) years after the first commercial sale of the Royalty-bearing Product by or under the authority of Unity in any country in the Territory. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 5.5 Royalty Stacking. Unity shall be entitled to deduct from the amounts owing to
Ascentage under Sections 5.2 and 5.3 above [***] percent ([***]%) of any royalties or other payments made to Third Parties for Enabling IP, provided that (a) the total aggregate amount payable to Ascentage under Sections 5.2 and 5.3 in
any [***] may not be reduced to less than [***] percent ([***]%) of the amounts that would otherwise be due Ascentage in such [***], and (b) Unity shall not be entitled to deduct any royalties or other payments made under the Existing
Agreements. If, in any [***], Unity is not able to fully recover its [***] percent ([***]%) portion of the payments due to a Third Party, it shall be entitled to carry forward such right of off-set to future
[***] with respect to the excess amount 
 5.6 Generic Products. If at any time during the term of this Agreement a Generic Product
enters the market in any country and has for a period of at least [***] ([***]) consecutive [***] a market share in such country of at least [***] percent ([***]%) of the then combined unit volume of the corresponding Royalty-bearing Product (i.e.,
the Royalty-bearing Product containing the same active pharmaceutical ingredient(s) as are present in the Generic Product) and such Generic Product, then Unity’s obligation to pay royalties to Ascentage on Net Sales of such Royalty-bearing
Product in such country shall be to reduced to [***] percent ([***]%) of the amounts that would otherwise be due Ascentage under Section 5.3 in such calendar quarter. 

5.7 Maximum Reduction to Royalties. Notwithstanding anything to the contrary in this Article 5, in no event shall the royalties owing to
Ascentage with respect to Net Sales of a Royalty-bearing Product in any country be reduced by cumulative operation of Sections 5.5 and 5.6 to less than [***] percent ([***]%) of the amounts that would otherwise be due Ascentage under
Section 5.3 in such calendar quarter. 
 5.8 Combination Products. In the event that a Royalty-bearing Product is sold for a
single price in combination with another therapeutically active pharmaceutical ingredient, or other product or service, for which no royalty would be due hereunder if sold separately, Net Sales from such combination sales, for purposes of
calculating the applicable royalty rate and the applicable royalty due under Section 5.3 shall be calculated by multiplying the Net Sales of the combination product by the fraction A/(A + B), where A is the average gross selling price during
the previous [***] of the Royalty-bearing Product sold separately and B is the gross selling price during the previous [***] of the therapeutically active ingredient, product or service. In the event that separate sales of the Royalty-bearing
Product or the additional therapeutically active ingredient, product or service were not made during the previous [***], then the Net Sales shall be reasonably allocated between such Royalty-bearing Product and such other active ingredient, product
or service as agreed upon by the Parties, or failing agreement, determined in accordance with Section 13.1 (Dispute Resolution) below. 

5.9 Unity’s Covenant. Unity hereby agrees that any shares of common stock issued to Ascentage will not be diluted unless diluted in
good faith by Unity on a proportionate basis to the other shares of common stock of Unity outstanding at the time of any such dilution, and subject to the anti-dilution protections as set forth in Unity’s certificate of incorporation, as may be
amended 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
from time to time in good faith; provided further, that Unity shall not take actions that specifically treat Ascentage differently from other holders of common stock, or issue any capital stock
in a manner which is intended to circumvent this covenant. The shares of common stock issued to Ascentage shall be duly adjusted for any bonus issue, share split, consolidation, subdivision, reclassification, recapitalization or similar arrangement
of Unity, in each case in accordance with, and as expressly contemplated by, Unity’s certificate of incorporation, as may be amended from time to time in good faith. 

ARTICLE 6 
 ACCOUNTING;
RECORDS; METHOD OF PAYMENT 
 6.1 Royalty Reports; Payments, Invoices. After the first sale of a Royalty-bearing Product on which
royalties are payable by Unity hereunder, Unity shall make quarterly written reports to Ascentage within [***] ([***]) days after the end of each calendar quarter, stating in each such report the number, description, and aggregate Net Sales of
Royalty-bearing Product sold during the calendar quarter upon which a royalty is payable under Article 5 above. Concurrently with the making of such reports, Unity shall pay to Ascentage all amounts payable pursuant to Article 5 above, in accordance
with the payment provisions of Section 6.3. 
 6.2 Records; Inspection. During the term of this Agreement and for a period of
[***] ([***]) years thereafter, Unity and its Affiliates shall keep complete, true and accurate books of account and records for the purpose of determining the amounts payable to Ascentage under this Agreement. Ascentage shall have the right to
cause an independent, certified public accountant reasonably acceptable to Unity to audit such records to confirm gross sales, Net Sales and royalty payments for a period covering not more than the preceding [***] ([***]) years. Unity agrees to
either: (a) require each of its Third Party Sublicensees to maintain similar books and records and to open such records for inspection by an independent, certified public accountant reasonably satisfactory to such Third Party Sublicensee, on
behalf of, and as required by, Ascentage for the purpose of verifying payments hereunder, or (b) obtain such audits rights from the Third Party Sublicensee for itself and exercise such audit rights on behalf of Ascentage upon Ascentage’s
request and disclose the results thereof to Ascentage. All such inspections may be made no more than once each calendar year at reasonable times and on reasonable notice. No accounting period of Unity or its Affiliate or Third Party Sublicensee
shall be subject to audit more than one time hereunder. Such independent, certified public accountant will be obliged to execute a reasonable confidentiality agreement prior to commencing any such inspection. The results of any inspection hereunder
shall be provided to both Parties, and Unity shall pay any underpayment to Ascentage within [***] ([***]) days. Inspections conducted under this Section 6.2 shall be at the expense of Ascentage (and Ascentage will reimburse Unity’s
reasonable out-of-pocket costs of those inspections conducted by Unity at Ascentage’s request under (b) above), unless a variation or error producing an
increase exceeding [***] percent ([***]%) of the amount stated for any period is established in the course of any such inspection, whereupon all costs of such audit of such period will be paid by Unity. 

6.3 Payment Method. All payments due hereunder shall be made in U.S. dollars, and shall be made by bank wire transfer in immediately
available funds to an account designated by Ascentage in a written notice to Unity. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rates used by
Unity in calculating Unity’s own revenues for financial reporting purposes. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 6.4 Late Payments. Any payments due from Unity that are not paid on the date such
payments are due under this Agreement shall bear interest at [***] ([***]%) above the then prevailing US Federal Funds Target Rate (Bloomberg page: FDTR <Index>) per annum calculated on a daily basis and payable for the period from the date
payment is due until the date payment is actually made. This Section 6.4 shall in no way limit any other remedies available to any Party. 

ARTICLE 7 
 PATENT
PROSECUTION AND ENFORCEMENT 
 7.1 Prosecution of Patents within the Licensed Intellectual Property. 

7.1.1 General. 
 (a)
Except as set forth in Section 7.1.1(b) or Section 7.1.1(c) hereof, Ascentage shall have the sole right to control the preparation, filing, prosecution and maintenance of all Licensed Patents using patent counsel of its choice. 

(b) Unity shall have the first right, but not the obligation, to prepare, file, prosecute and maintain Royalty-bearing Product-Specific
Patents. Unity shall (i) keep Ascentage reasonably informed as to its filing and prosecution strategy for Royalty-bearing Product-Specific Patents and the filing, prosecution and maintenance of Royalty-bearing Product-Specific Patents,
(ii) provide Ascentage with a reasonable opportunity to review drafts of proposed patent office submissions with respect to Royalty-bearing Product-Specific Patents; and (iii) consider in good faith the requests and suggestions of
Ascentage with respect to strategies for filing and prosecuting such Royalty-bearing Product-Specific Patents. In the event that Unity desires to abandon or decline further responsibility for any such Royalty-bearing Product-Specific Patent, Unity
shall provide reasonable prior written notice to Ascentage of such intention to abandon or decline responsibility, but in no case later than [***] ([***]) days prior to any required action relating to the filing, prosecution or maintenance of such
Royalty-bearing Product-Specific Patent, and Ascentage shall have the right, at its discretion, to assume such responsibility. 
 (c) With
respect to any Licensed Patent (other than a Royalty-bearing Product-Specific Patent) that claims the Licensed Compound, a Licensed Product or Unity Bcl-2 [***] Product, Ascentage shall have the first right,
but not the obligation, to prepare, file, prosecute and maintain such Licensed Patent and shall (i) keep Unity reasonably informed as to its filing and prosecution strategy for such Licensed Patent and the filing, prosecution and maintenance of
such Licensed Patent, (ii) provide Unity with a reasonable opportunity to review drafts of proposed patent office submissions with respect to such Licensed Patent; and (iii) follow the directions given by Unity with respect to filing and
prosecuting such Licensed Patents, unless [***], in which case [***] and [***]. In the event that Ascentage desires to abandon or decline further responsibility for any Licensed Patent, Ascentage shall provide Unity [***] notice and the opportunity
to assume responsibility for such Licensed Patent. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 7.1.2 For purposes of this Article 7, “prosecution and maintenance” of patents and
patent applications shall be deemed to include, without limitation, the conduct of interferences or oppositions, and/or requests for re-examinations, reissues or extensions of patent terms. 

7.2 Enforcement of Licensed Patents. If either Party determines that a Third Party is making, using or selling a product that may
infringe any Licensed Patent, that Party shall notify the other Party in writing. 
 7.2.1 Infringement by a Competitive Product. 

(a) With respect to any such infringing activity that involves the manufacture, use or sale by a Third Party of any product that [***]
(“Competitive Product”), Unity shall have the first right, at its sole option, to bring suit to enforce any Licensed Patent, and/or to defend any declaratory judgment action with respect thereto (“Enforcement
Action”); provided, however, that Unity shall keep Ascentage reasonably informed as to the defense and/or settlement of any such Enforcement Action. Ascentage shall have the right to participate in any such Enforcement Action with counsel
of its own choice at its own expense. All recoveries received by Unity from an Enforcement Action shall be first applied to reimburse Unity’s and then Ascentage’s unreimbursed expenses, including without limitation, reasonable
attorney’s fees and court costs. Any remainder shall, to the extent the same pertains to an infringing activity that involves the manufacture, use or sale by a Third Party of any Competitive Product, be treated as Net Sales. 

(b) In the event Unity elects not to initiate an Enforcement Action with respect to any commercially significant infringing activity that
involves the manufacture, use or sale by a Third Party of any Competitive Product within [***] ([***]) days of a request by Ascentage to do so ([***]), Ascentage may initiate such action at its expense. Unity shall have the right to participate in
any such action with counsel of its own choice at its own expense. All recoveries received by Ascentage from an Enforcement Action shall be first applied to reimburse Ascentage’s and then Unity’s unreimbursed expenses, including without
limitation, reasonable attorney’s fees and court costs. Any remainder shall, to the extent the same pertains to an infringement of the Licensed Patents, be split [***]. 

7.2.2 Other Instances of Infringement. With respect to any such infringing activity that does not involve the manufacture, use or sale
by a Third Party of a Competitive Product, Ascentage shall have the sole right, at its sole option, to bring suit to enforce any Licensed Patent, and/or to defend any declaratory judgment action with respect thereto and to retain all recoveries
received by Ascentage in connection therewith. 
 7.3 Infringement Claims Against Unity. If the production, sale or use of a
Royalty-bearing Product pursuant to this Agreement results in any claim, suit or proceeding alleging patent infringement against Unity (or its Affiliates or sublicensees), Unity shall promptly notify Ascentage thereof in writing setting forth the
facts of such claim in reasonable detail. As between the Parties, Unity will be entitled to control the defense in any such action(s). Unity agrees to keep Ascentage reasonably informed of all material developments in connection with any such claim,
suit or proceeding as it relates to the Licensed Intellectual Property. Notwithstanding the above, Unity shall not admit the invalidity of any Licensed Patent without written consent from Ascentage. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 7.4 Cooperation. In any legal action undertaken by a Party pursuant to
Sections 7.2 or 7.3 of this Agreement (the Party bringing or defending such legal action, the “Enforcing Party”), the non-Enforcing Party shall cooperate fully with the Enforcing Party,
including without limitation by joining as a party plaintiff if necessary for legal standing and executing such documents as the Enforcing Party may reasonably request. Upon the request of, and at the expense of, the Enforcing Party, the non-Enforcing Party shall make available at reasonable times and under appropriate conditions all relevant personnel, records, papers, information, samples, specimens and other similar materials in its possession.

 7.5 No Implied Obligations. Except as expressly provided in this Article 7, neither Party has any obligation to bring or prosecute
actions or suits against any Third Party for patent infringement. 
 7.6 UM License Agreement. Notwithstanding the foregoing
provisions of this Article 7, with respect to the Licensed Patents subject of the UM License Agreement, Unity’s rights under this Article 7 shall be limited to the extent of Ascentage’s rights to prosecute and enforce such Licensed Patents
under the UM License Agreement, provided that (a) with respect to Royalty-bearing Product-Specific Patents that have been in-licensed from UM, to the extent the UM License Agreement will not permit
Unity to control the prosecution of such patents, Ascentage agrees to (i) share with Unity the information Ascentage receives from UM under Section 7.2 of the UM License Agreement with respect to such patents, (ii) provide Unity with
a reasonable opportunity to review and comment upon such information; and (iii) pass along to UM Unity’s comments and requested actions, and (b) Ascentage shall at Unity’s request and expense cooperate with Unity in order to
allow Unity to exercise on Ascentage’s behalf the enforcement rights granted to Ascentage under Section 8.1 of the UM License Agreement, in each case as permitted by the UM License Agreement. 

OPTION FOR CHINA JOINT VENTURE 
 7.6
Option for China JVCO. Unity shall grant to Ascentage an option to commercialize one or more Royalty-bearing Products for use in the Field in Greater China jointly with Unity through a joint venture entity (“China JVCO”) to
be established in accordance with Section 8.4 of the Library Agreement(“JVCO Option”). The process for exercise of the JVCO Option shall be agreed upon by [***] and [***] at [***]. 

7.7 Limitation of Obligations; Certain Covenants 

8.2.1. Notwithstanding anything to the contrary, nothing in this Agreement shall be deemed to have granted Unity or any of its
sublicensees the right to develop, manufacture, distribute, sell or otherwise commercialize the Royalty-bearing Products in the Greater China. 

8.2.2 Ascentage hereby covenants that it shall not develop, manufacture, distribute, sell or otherwise commercialize (a) Unity Bcl-2 [***] Products or (b) the Licensed Compound (including any Licensed Products containing the Licensed Compound) for use in the Field in the Greater China except through the China JVCO. In the event of a
breach by Ascentage of its obligations under this Section 8.2.2, the [***] and [***], shall [***]. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 8.2.3 Unity and Ascentage hereby covenant that they shall cooperate with respect to the
establishment of the China JVCO, including without limitation by (a) initiating negotiation of the form agreements relating to the JVCO within [***] of the Effective Date, (b) using commercially reasonable efforts to reach agreement on
such form agreements within [***] ([***]) [***] of the Effective Date, including ensuring that [***] and [***] devote at least [***] to such negotiations until such form agreements are agreed upon, and (c) signing the agreements for
establishment of the China JVCO agreed upon by [***] and [***]. 
 CONFIDENTIALITY 

7.8 Confidential Information. Except as otherwise expressly provided herein, the parties agree that the receiving party shall not,
except as expressly provided in this Article 9, disclose to any Third Party or use for any purpose any information which is disclosed to it by the other party, whether orally or in writing, and identified as confidential (“Confidential
Information”), except to the extent that it can be established by the receiving party by competent proof that such information: 

(a) Was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 

(b) Was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; 

(c) Became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or
omission of the receiving party in breach of this Agreement; 
 (d) Was independently developed by the receiving party without reference to
information provided by the disclosing party as demonstrated by documented evidence prepared contemporaneously with such independent development; or 

(e) Was disclosed to the receiving party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the
disclosing party not to disclose such information to others. 
 7.9 Permitted Use and Disclosures. Each party hereto may use or
disclose Confidential Information of the other party to the extent such use or disclosure is reasonably necessary in the following instances: (a) exercising the rights granted to it hereunder (including, in the case of Unity, developing,
commercializing and/or sublicensing of Royalty-bearing Products) or in carrying out its obligations hereunder; (b) filing or prosecuting Patents as permitted by this Agreement; (c) prosecuting or defending litigation; and
(d) complying with applicable court orders or governmental regulations. Notwithstanding the foregoing, in the event a party is required to make a disclosure of the other party’s Confidential Information pursuant to clause (c) or
(d) of this Section 9.2, it will, except where impracticable, give reasonable advance notice to the disclosing 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
party of such disclosure and use efforts to secure confidential treatment of such information at least as diligent as such party would use to protect its own confidential information, but in no
event less than reasonable efforts. In addition, Unity shall have the right to disclose Confidential Information regarding the Licensed Compound or Licensed Products to Third Parties in connection with due diligence or similar investigations, to
potential Third Party investors, and others on a need to know basis, in each case under terms of confidentiality that are appropriate for the circumstances, or to the extent required by law. 

7.10 Nondisclosure of Terms. Each of the parties hereto agrees not to disclose the terms of this Agreement to any Third Party without
the prior written consent of the other party hereto, which consent shall not be unreasonably withheld; provided that a party may disclose the terms of this Agreement without such consent to such party’s attorneys and advisors, to Third Parties
in connection with due diligence or similar investigations, to potential Third Party investors, and others on a need to know basis, in each case under terms of confidentiality that are appropriate for the circumstances, or to the extent required by
law. 
 7.11 Public Announcement. Unity may, in its discretion, issue a press release announcing the formation of this Agreement,
which shall be substantially in a form approved by Ascentage prior to execution of the Agreement. Except with respect to such initial release or as otherwise required by law, neither party shall issue an additional press release or public
announcement relating to this Agreement without the prior written approval of the other party, which shall not be withheld unreasonably. Either party may refer to the license granted under this Agreement in promotional and other communications with
prospective customers and investors, subject to the prior written approval of the other party of the form, substance and intended use of such reference, and provided that such disclosure shall not include any technical details or any financial terms
of the license. For purposes of clarification, after a party has obtained the other party’s written approval of the form, substance and intended use of a particular reference, no further approval of the other party will be required for
inclusion of the same reference in future communications that are intended for the same use. 
 ARTICLE 8 

INDEMNIFICATION 
 8.1
Unity. Unity agrees to indemnify and defend Ascentage and its directors, officers, employees, agents and their respective successors, heirs and assigns (the “Ascentage Indemnitees”) against any losses, costs, claims, damages,
liabilities or expense (including reasonable attorneys’ and professional fees and other expenses of litigation) (collectively, “Liabilities”) arising, directly or indirectly out of or in connection with Third Party claims,
suits, actions, demands or judgments, to the extent (a) relating to Licensed Products developed, manufactured, used, sold or otherwise distributed by or on behalf of Unity, its Affiliates, sublicensees or other designees (excluding Ascentage,
its Affiliates and licensees) including, without limitation, product liability and patent infringement claims, or (b) resulting from a breach by Unity of its representations and warranties under this Agreement, except, in each case, to the
extent such Liabilities result from the negligence or intentional misconduct of Ascentage or Ascentage’s breach of its representations and warranties under this Agreement or the Supply Agreement to be negotiated pursuant to Article 4 above.

 EXECUTION COPY 

CONFIDENTIAL 
  

 8.2 Ascentage. Ascentage agrees to indemnify and defend Unity and its directors,
officers, employees, agents and their respective heirs and assigns (the “Unity Indemnitees”) against any Liabilities arising, directly or indirectly out of or in connection with Third Party claims, suits, actions, demands or
judgments, to the extent resulting from a breach by Ascentage of its representations and warranties under this Agreement or the Supply Agreement to be negotiated pursuant to Article 4 above, except, in each case, to the extent such Liabilities
result from the negligence or intentional misconduct of Unity or Unity’s breach of its representations and warranties under this Agreement. 

8.3 Procedure. In the event that any party intends to claim indemnification under this Article 10 (each such party, an
“Indemnitee”) it shall promptly notify the other Party in writing of such alleged Liability. The indemnifying Party shall have the right to control the defense thereof with counsel of its choice as long as such counsel is reasonably
acceptable to Indemnitee; provided, however, that any Indemnitee shall have the right to retain its own counsel at its own expense, for any reason, including if representation of any Indemnitee by the counsel retained by the indemnifying Party would
be inappropriate due to actual or potential differing interests between such Indemnitee and any other Party reasonably represented by such counsel in such proceeding. The indemnifying Party shall keep the Indemnitee regularly informed of the status
of the defense of any action, claim or liability covered by this Article 10 and shall take into consideration the Indemnitee’s reasonable comments thereon. The affected Indemnitee shall cooperate with the indemnifying Party and its legal
representatives in the investigation of any action, claim or liability covered by this Article 10. The Indemnitee shall not compromise or settle any claim or suit, or voluntarily incur any expense with respect to any such claim or suit, in each
case, without the prior written consent of the indemnifying Party, which such Party shall not be required to give. The failure to deliver written notice to the indemnifying Party within a reasonable time after the commencement of any action with
respect to any action, claim or liability covered by this Article 10, if prejudicial to its ability to defend such action, shall relieve the indemnifying Party of any liability to the Indemnitee under this Article 10. 

ARTICLE 9 

REPRESENTATIONS AND WARRANTIES 

9.1 General Warranties. Each Party represents and warrants to the other Party that it is a corporation duly organized and validly
existing under the laws of the state or country of its incorporation, the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite corporate action, and it has the power and authority to execute
and deliver this Agreement and to perform its obligations hereunder (including, in the case of Ascentage, granting the rights and licenses described in Article 2). 

9.2 Ascentage Warranties. Ascentage represents and warrants on its own behalf and on behalf of its Affiliates that as of the Effective
Date: 
 (a) except as otherwise disclosed to Unity in writing prior to the Effective Date, (i) Ascentage has not received written
notice from a Third Party claiming that the Licensed Compound infringes the intellectual property rights of any Third Party, and (ii) Ascentage is not a party to any legal action, suit or proceeding relating to the Licensed Compound. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 (b) except as otherwise disclosed to Unity in writing prior to the Effective Date, there are
no actual or pending actions, suits or claims, by any Third Party (i) challenging the ownership of the Licensed Compound; or (b) challenging the validity, effectiveness, enforceability, or ownership of the Licensed Intellectual Property.

 (c) except as otherwise disclosed to Unity in writing prior to the Effective Date, the Licensed Patents are subsisting, in force or
pending, as the case may be, and are not the subject of any interference, reissue, reexamination, opposition, cancellation or similar administrative proceedings. 

(d) except as otherwise disclosed to Unity in writing prior to the Effective Date, Ascentage has not brought a claim alleging an infringement
by a Third Party of any of the Licensed Patents and to Ascentage’s actual knowledge, there is no actual or alleged infringement by a Third Party of any of the Patents within the Licensed Patents. 

(e) there are no Patents: (a) filed by Ascentage and subsequently assigned to Third Party, or (b) with respect to which Ascentage or
its Affiliates have acquired rights from a Third Party (i.e., through in-licenses, cross-licenses or otherwise), in each case that (i) would be required for Unity to research, develop, manufacture, use or
commercialize the Licensed Compound and (ii) are not included within the Licensed Intellectual Property. 
 (f) except as otherwise
disclosed to Unity in writing prior to the Effective Date, there are no actual or pending suits or claims by any Third Party asserting that the manufacture, use, sale, offer for sale or importing of the Licensed Compound infringes the intellectual
property of a Third Party and to Ascentage’s knowledge, the development and commercialization of the Licensed Compound would not infringe (i) any issued Patents of any Third Party (other than Patents
in-licensed from UM), or (ii) any published Patent claim of any Third Party (other than claims of Patents in-licensed from UM) if such claim were to issue as
published. 
 (g) Ascentage has disclosed to Unity all material agreements with Third Parties in effect as of the Effective Date pursuant to
which Licensed Intellectual Property was licensed, acquired or sold, including without limitation all amendments to the UM License Agreement entered into by UM and Ascentage subsequent to the effective date of the License Agreement. 

(h) Ascentage has not previously granted and will not grant any rights in the Licensed Intellectual Property that are inconsistent with the
rights and licenses granted to Unity herein. 
 9.3 Certain Rights and Obligations under the UM License Agreement. 

(a) Ascentage shall not modify, amend or otherwise alter the UM License Agreement to the extent the same would materially and adversely affect
Unity’s rights under this Agreement. 
 (b) Ascentage shall not (a) exercise or fail to exercise any right under the UM License
Agreement or (b) provide or fail to provide any consent or approval with respect to any right or obligation under the UM License Agreement, in each case to the extent the same would materially and adversely affect Unity’s rights under this
Agreement. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 (c) Ascentage shall not unilaterally terminate the UM License Agreement. 

9.4 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY
WARRANTIES TO THE OTHER PARTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, REGARDING THE LICENSED COMPOUND, LICENSED PRODUCTS, UNITY BCL-2 SYSTEMIC PRODUCTS OR THE LICENSED INTELLECTUAL PROPERTY, INCLUDING, BUT NOT
LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, AND VALIDITY OF LICENSED INTELLECTUAL PROPERTY CLAIMS, ISSUED OR PENDING. 

9.5 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 9, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE
OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT; provided, however, that this Section 11.5 shall not be construed to limit either party’s indemnification obligations under
Article 10. 
 ARTICLE 10 

TERM AND TERMINATION 
 10.1
Term. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article 12, shall continue in full force and effect on a
country-by-country basis until the expiration of all royalty obligations pursuant to this Agreement for such country, as provided in Section 5.4 above. Unity’s
license with respect to the Licensed Technology shall survive the expiration (but not an earlier termination) of this Agreement, provided that such license shall thereafter become nonexclusive and fully
paid-up. 
 10.2 Termination for Breach. Either Party may terminate this Agreement in the
event that the other Party shall have materially breached or defaulted in the performance of any of its material obligations hereunder, and such breach or default shall have continued for sixty (60) days after written notice of such breach and
intent to terminate this Agreement therefor was provided to the breaching Party by the nonbreaching Party. Any such termination shall become effective at the end of such sixty (60) day period unless the breaching Party has cured any such breach
or default prior to the expiration of the sixty (60) day period. Notwithstanding the foregoing, if the Party alleged to be in breach of this Agreement in good faith disputes such breach within such sixty (60) day period, the nonbreaching
Party shall not have the right to terminate this Agreement unless it has been determined by arbitration pursuant to Section 13.2 that this Agreement was materially breached, and the breaching Party fails to comply with its obligations hereunder
within sixty (60) days after such determination. 
 10.3 Termination by Unity. Any provision herein notwithstanding, Unity may
terminate this Agreement, in its entirety or as to any particular Patent within the Licensed Patents, or as to any particular Licensed Product, at any time by giving Ascentage at least ninety (90) days prior written

 EXECUTION COPY 

CONFIDENTIAL 
  

 
notice. From and after the effective date of a termination under this Section 12.3 with respect to a particular Patent in a particular country, such Patent shall cease to be within the
Licensed Patents for all purposes of this Agreement, and all rights and obligations of Unity with respect to such Patent(s) shall terminate. From and after the effective date of a termination under this Section 12.3 with respect to a particular
Licensed Product, the license granted under Section 2.1 above shall terminate with respect to such Licensed Product, and the same shall cease to be a Licensed Product for all purposes of this Agreement. Upon a termination of this Agreement in
its entirety under this Section 12.3, all rights and obligations of the parties shall terminate, except as provided in Section 12.4 below. For clarity, Unity shall remain obligated to pay any and all milestone and other payments accrued,
due and payable to Ascentage prior to such termination. 
 10.4 Effect of Termination. 

10.4.1 Accrued Obligations. Expiration or any termination of this Agreement shall not release either Party hereto from any liability
which at the time of such expiration or termination has already accrued to such Party or which is attributable to a period prior to such expiration or termination, subject to the terms of this Agreement, nor preclude either Party from pursuing any
rights and remedies it may have hereunder or at law or in equity which accrued to it prior to such expiration or termination, subject to the terms of this Agreement. 

10.4.2 Sales of Existing Inventory of Licensed Product. In the event this Agreement is terminated for any reason with respect to a
Licensed Product after the first approval of an MAA for such Licensed Product, Unity shall provide Ascentage with a written inventory of all quantities of such Licensed Product that Unity and its Affiliates have in stock and, for a period of [***]
([***]) [***] after such termination, Unity and its Affiliates shall have the right to sell or otherwise dispose of such Licensed Product, all subject to the payment to Ascentage of royalties pursuant to Article 5 hereof. 

10.4.3 Survival of Sublicenses. Upon termination of this Agreement for any reason, any sublicense granted by Unity hereunder to a Third
Party Sublicensee shall survive, provided that such Third Party Sublicensee continues to pay to Ascentage the milestones and royalties that would have been due to Ascentage under this Agreement based on such Third Party Sublicensee’s activities
had this Agreement not terminated. For clarity, in the event that a Third Party Sublicensee fails to pay to Ascentage the applicable milestones and royalties due to Ascentage based on such Third Party Sublicensee’s activities, Ascentage shall
be entitled to terminate such surviving sublicense by providing such Third Party Sublicensee written notice of termination, which notice shall take effect [***] ([***]) days after it is received by such Third Party Sublicensee unless such Third
Party Sublicensee has cured any such breach or default prior to the expiration of the [***] ([***]) day period. 
 10.4.4 Library
Agreement. This Agreement is independent of, and shall not be affected by, the expiration or termination of the Library Agreement, and vice versa. 

10.4.5 Survival. Articles 1 (Definitions), 6 (Accounting; Records; Method of Payment), 9 (Confidentiality), 10 (Indemnification), 13
(Dispute Resolution) and 14 (Miscellaneous), and Sections 2.1.1(b), 2.1.2(c), 5.2.2, 5.3.2 and 5.4-5.8, (with respect to [***]), 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
7.2.1 (with respect to any ongoing Enforcement Action), 11.3, 11.4 and 12.4 shall survive the expiration or termination of this Agreement for any reason, provided that such survival shall be
contingent upon Unity having fulfilled its obligations under Section 5.1.1. Except as otherwise provided in this Article 12, all rights and obligations of the parties under this Agreement shall terminate upon the expiration or termination of
this Agreement. 
 10.5 Condition Precedent. 

10.5.1 This Agreement is entered into subject to the condition precedent that Ascentage and UM agree upon and execute an amendment to the UM
License Agreement (“Second Amendment”) adjusting the royalties owing to UM in connection with the activities contemplated by this Agreement (including the attached Exhibits). All rights and obligations set forth in the Agreement
shall only become effective upon the Effective Date. 
 10.5.2 Ascentage hereby agrees to use its commercially best efforts to complete and
execute the Second Amendment as soon as reasonably practicable. 
 ARTICLE 11 

DISPUTE RESOLUTION 
 11.1
Dispute Resolution. If an unresolved dispute arises out of or relates to this Agreement, or the breach thereof, either Party may refer such dispute to the [***] of Unity and Ascentage, who shall meet in person or by telephone within [***]
([***]) days after such referral to attempt in good faith to resolve such dispute. If such matter cannot be resolved by discussion of such officers within such [***] ([***]) days period (as may be extended by mutual agreement), either Party shall be
entitled to seek resolution of such dispute pursuant to Section 13.2 below. 
 11.2 Arbitration. If the parties are unable to
resolve a dispute on an issue of interpretation, breach or enforcement of this Agreement, the parties shall refer such dispute to be finally resolved by binding arbitration under the terms of this Section 13.2, except that all disputes with
respect to the validity or infringement of Patents shall be subject to applicable federal court jurisdiction and not subject to the terms of this Section 13.2. Whenever a party shall decide to institute arbitration proceedings, it shall give
written notice to that effect to the other party. Any such arbitration shall be conducted under the [***] by a panel of three (3) arbitrators in [***]. Each party shall select one (1) arbitrator who is not employed by, or otherwise
affiliated with, such party within [***] ([***]) days after the institution of arbitration proceedings, and the two (2) arbitrators so selected shall designate the third arbitrator. The parties shall use their commercially reasonable efforts to
conclude the arbitration hearings within [***] ([***]) [***] following the confirmation of the third and presiding arbitrator. 
 11.3
Injunctive Relief. Each Party shall be free to seek preliminary or permanent injunctive relief, restraining order or degree of specific performance in any court of competent jurisdiction. For avoidance of doubt, any such equitable remedies
provided under this Section 13.3 shall be cumulative and not exclusive and are in addition to any other remedies, which either Party may have under this Agreement or applicable law. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 ARTICLE 12 

MISCELLANEOUS 
 12.1
Governing Laws. This Agreement and any dispute arising from the construction, performance or breach hereof shall be governed by and construed, and enforced in accordance with, the laws of the state of New York, USA, without reference to
conflicts of laws principles. 
 12.2 Waiver. It is agreed that no waiver by either Party hereto of any breach or default of any of
the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default. 
 12.3
Assignment. This Agreement shall not be assignable by either party without the written consent of the other party hereto, except that either party may assign this Agreement, without such consent, to an entity that acquires all or
substantially all of the business or assets of such party to which this Agreement relates, whether by merger, reorganization, acquisition, sale, or otherwise; provided, however, that within [***] ([***]) days of such an assignment, the assignee
shall agree in writing to be bound by the terms and conditions of this Agreement. Subject to the foregoing, this Agreement shall bind and inure to the benefit of each party’s successors and permitted assigns. 

12.4 Independent Contractors. The relationship of the Parties hereto is that of independent contractors. The Parties hereto are not
deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the transactions contemplated thereby. 

12.5 Compliance with Laws. In exercising their rights under this Agreement, the Parties shall fully comply in all material respects with
the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this license including, without limitation, those applicable to the discovery, development,
manufacture, distribution, import and export and sale of Licensed Products pursuant to this Agreement. 
 12.6 Notices. All notices,
requests and other communications hereunder shall be in writing and shall be personally delivered or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other
address as may be specified in writing to the other Parties hereto and shall be deemed to have been given upon receipt: 
  

	 	If to Unity:	Unity Biotechnology, Inc. 

 1700 Owens Street, Suite 535 

San Francisco, CA 94158, USA 

Attention: [***] 
 Email: [***]

  

	 	If to Ascentage:	Ascentage Pharma Group Corp. Ltd. 

 Room 201, QB3 Building, Medical City Avenue 

Hi-Tech BioMed District, Taizhou City, Jiangsu Province 

P.R. China, 225300 
 Attention:
[***] 
 Email: [***] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

CONFIDENTIAL 
  

 12.7 Severability. In the event that any provision of this Agreement becomes or is
declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the Parties shall amend the Agreement to
the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the Parties and their commercial bargain. 

12.8 Advice of Counsel. Unity and Ascentage have each consulted counsel of their choice regarding this Agreement, and each acknowledges
and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. 
 12.9
Performance Warranty. Each Party hereby warrants and guarantees the performance of any and all rights and obligations of this Agreement by its Affiliates, licensees and sublicensees. 

12.10 Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses (except for
payment obligations) on account of failure of performance by the defaulting Party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout, embargo, unusual and unexpected governmental intervention, failure of
suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing Party and such Party has
exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance. 

12.11 Complete Agreement. This Agreement with its schedules, together with the Library Agreement and its exhibits, constitutes the
entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are
null and void and of no effect. No amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto unless reduced to writing and executed by the respective duly authorized representatives of Unity and
Ascentage. 
 12.12 Headings. The captions to the several Sections and Articles hereof are not a Part of this Agreement, but
are included merely for convenience of reference and shall not affect its meaning or interpretation. 
 12.13 Counterparts. This
Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. 

12.14 Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by each Party as a licensor are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of Title ll, U.S. Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined under section 101(35A) of the Bankruptcy Code.
The Parties agree that each licensee of such rights 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
under this Agreement, shall retain and may fully exercise all rights and elections it would have in the case of a licensor bankruptcy under the Bankruptcy Code. Each Party agrees during the term
of this Agreement to create or maintain current copies, or if not amenable to copying, detailed descriptions or other appropriate embodiments, of all such intellectual property licensed to the other Party. 

IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Agreement. 

 

									
	ASCENTAGE PHARMA GROUP CORP. LTD.	  		  	UNITY BIOTECHNOLOGY, INC.
					
	By:	 	 /s/ Dajun Yang
	  		  	By:	 	 /s/ Nathaniel David

			
	Name: Dajun Yang, MD, PhD	  		  	Name: Nathaniel David, PhD
			
	Title: Chief Executive Officer	  		  	Title: Chief Executive Officer

 EXECUTION COPY 

CONFIDENTIAL 
  

SCHEDULE 1.2 
 APG-1252 
 [***] 

Confidential Information 
 (Property of Ascentage
Pharma Group) 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 SCHEDULE 5.1 

FORM OF STOCK ISSUANCE AGREEMENT 

UNITY BIOTECHNOLOGY, INC. 

RESTRICTED STOCK GRANT AGREEMENT 

This Restricted Stock Grant Agreement (the “Agreement”) is made as of [•] by and between Unity Biotechnology, Inc., a
Delaware corporation (the “Company”), and Ascentage Pharma Group Corp. Ltd. (the “Grantee”). 
 In
consideration of the mutual covenants and representations set forth below, the Company and Grantee agree as follows: 
 1. Grant of the
Shares. Subject to the terms and conditions of this Agreement, the Company agrees to grant to Grantee, and Grantee agree to acquire from the Company, on the Closing (as defined below) [•] shares of the Company’s Common Stock, $0.0001
par value per share (the “Shares”), as consideration for services to be provided by Grantee to the Company. 
 2.
Closing. The transfer of the Shares shall occur at a closing (the “Closing”) to be held on the date first set forth above, or at any other time mutually agreed upon by the Company and Grantee. The Closing will take place at
the principal office of the Company or at such other place as shall be designated by the Company. As promptly after the Closing as practicable, the Company will issue a stock certificate, registered in the name of Grantee, reflecting the Shares.

 3. Restrictions on Transfer. 

A. Investment Representations and Legend Requirements. The Grantee hereby make the investment representations listed on Exhibit A
to the Company as of the date of this Agreement and as of the date of the Closing, and agrees that such representations are incorporated into this Agreement by this reference, such that the Company may rely on them in issuing the Shares. Grantee
understand and agree that the Company shall cause the legends set forth below, or substantially equivalent legends, to be placed upon any certificate(s) evidencing ownership of the Shares, together with any other legends that may be required by the
Company or by applicable state or federal securities laws: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR UNLESS THE
COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED. 

 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER, A
RIGHT OF FIRST REFUSAL, AND A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE RESTRICTED STOCK GRANT AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL
HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL AND LOCK-UP PERIOD ARE BINDING ON TRANSFEREES OF THESE SHARES.

 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED
FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO TRANSFER MAY BE EFFECTED WITHOUT AN EFFCTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 B. Stop-Transfer Notices. Grantee
agree that to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make
appropriate notations to the same effect in its own records. 
 C. Refusal to Transfer. The Company shall not be required (i) to
transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any acquirer or
other transferee to whom such Shares shall have been so transferred 
 D. Lock-Up Period.
Grantee hereby agree that Grantee shall not sell, offer, pledge, contract to sell, grant any option or contract to purchase, purchase any option or contract to sell, grant any right or warrant to purchase, lend or otherwise transfer or encumber,
directly or indirectly, any Shares or other securities of the Company, nor shall Grantee enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Shares or
other securities of the Company, during the period from the filing of the first registration statement of the Company filed under the Securities Act of 

  
 2 

 
1933, as amended (the “Securities Act”), that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act
through the end of the 180-day period following the effective date of such registration statement (or such other period as may be requested by the Company or the underwriters to accommodate regulatory
restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any
successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the
future. Grantee further agree, if so requested by the Company or any representative of its underwriters, to enter into such underwriter’s standard form of “lockup” or “market standoff” agreement in a form satisfactory to the
Company and such underwriter. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of any such restriction period. 

4. Company’s Right of First Refusal. Before any Shares acquired by the Grantee pursuant to this Agreement (or any beneficial
interest in such Shares) may be sold, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by the Grantee or any subsequent transferee (each a “Holder”), such Holder must first offer
such Shares or beneficial interest to the Company and/or its assignee(s) as follows: 
 A. Notice of Proposed Transfer. The Holder
shall deliver to the Company a written notice stating: (i) the Holder’s bona fide intention to sell or otherwise transfer the Shares; (ii) the name of each proposed transferee; (iii) the number of Shares to be transferred to each
proposed transferee; (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the Shares; and (v) that by delivering the notice, the Holder offers all such Shares to the Company and/or its assignee(s)
pursuant to this section and on the same terms described in the notice. 
 B. Exercise of Right of First Refusal. At any time within
30 days after receipt of the Holder’s notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the
proposed transferees, at the purchase price determined in accordance with Section 4.C. 
 C. Purchase Price. The purchase price
for the Shares purchased by the Company and/or its assignee(s) under this section shall be the price listed in the Holder’s notice. If the price listed in the Holder’s notice includes consideration other than cash, the cash equivalent
value of the non-cash consideration shall be determined by the Board of Directors of the Company in its sole discretion. 

D. Payment. Payment of the purchase price shall be made, at the option of the Company and/or its assignee(s), in cash (by check), by
cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company and/or its assignee(s), or by any combination thereof within 30 days after receipt by the Company of the Holder’s notice (or at such later date as is
called for by such notice). 

  
 3 

 E. Holder’s Right to Transfer. If all of the Shares proposed in the notice to be
transferred to a given proposed transferee are not purchased by the Company and/or its assignee(s) as provided in this section, then the Holder may sell or otherwise transfer such Shares to that proposed transferee; provided that:
(i) the transfer is made only on the terms provided for in the notice, with the exception of the purchase price, which may be either the price listed in the notice or any higher price; (ii) such transfer is consummated within 60 days after
the date the notice is delivered to the Company; (iii) the transfer is effected in accordance with any applicable securities laws, and if requested by the Company, the Holder shall have delivered an opinion of counsel acceptable to the Company
to that effect; and (iv) the proposed transferee agrees in writing to receive and hold the Shares so transferred subject to all of the provisions of this Agreement, including but not limited to this section, and there shall be no further
transfer of such Shares except in accordance with the terms of this section. If any Shares described in a notice are not transferred to the proposed transferee within the period provided above, then before any such Shares may be transferred, a new
notice shall be given to the Company, and the Company and/or its assignees shall again be offered the right of first refusal described in this section. 

F. Exception for Certain Family Transfers. Notwithstanding anything to the contrary contained elsewhere in this section, the transfer of
any or all of the Shares during the Holder’s lifetime or on the Holder’s death by will or intestacy to (i) the Holder’s spouse; (ii) the Holder’s lineal descendants or antecedents, siblings, aunts, uncles, cousins,
nieces and nephews (including adoptive relationships and step relationships), and their spouses; (iii) the lineal descendants or antecedents, siblings, cousins, aunts, uncles, nieces and nephews of Holder’s spouse (including adoptive
relationships and step relationships), and their spouses; and (iv) a trust or other similar estate planning vehicle for the benefit of the Holder or any such person, shall be exempt from the provisions of this section; provided that, in
each such case, the transferee agrees in writing to receive and hold the Shares so transferred subject to all of the provisions of this Agreement, including but not limited to this section, and there shall be no further transfer of such Shares
except in accordance with the terms of this section; and provided further, that without the prior written consent of the Company, which may be withheld in the sole discretion of the Company, no more than three transfers may be made pursuant
to this section, including all transfers by the Holder and all transfers by any transferee. 
 G. Termination of Right of First
Refusal. The right of first refusal contained in this section shall terminate as to all Shares acquired hereunder upon the earlier of: (i) the closing date of the first sale of Common Stock of the Company to the general public pursuant to a
registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act, and (ii) the closing date of a Change of Control pursuant to which the holders of the outstanding voting securities of
the Company receive securities of a class registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. For purposes of this Agreement, a “Change of Control” means either: (i) the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation or stock transfer, but excluding any such transaction effected primarily for the
purpose of changing the domicile of the Company), unless the Company’s stockholders of record immediately prior to such transaction or series of related transactions hold, immediately after such transaction or series of related

  
 4 

 
transactions, at least 50% of the voting power of the surviving or acquiring entity (provided that the sale by the Company of its securities for the purposes of raising additional funds
shall not constitute a Change of Control hereunder); or (ii) a sale of all or substantially all of the assets of the Company. 
 5.
General Provisions. 
 A. Choice of Law. This Agreement shall be governed by the internal substantive laws, but not the choice
of law rules, of the State of California. 
 B. Integration. This Agreement, including all exhibits hereto, represents the entire
agreement between the parties with respect to the acquisition of the Shares by the Grantee and supersedes and replaces any and all prior written or oral agreements regarding the subject matter of this Agreement including, but not limited to, any
representations made during any interviews, relocation discussions or negotiations whether written or oral. 
 C. Notices. Any notice,
demand, offer, request or other communication required or permitted to be given by either the Company or the Grantee pursuant to the terms of this Agreement shall be in writing and shall be deemed effectively given the earlier of (i) when
received, (ii) when delivered personally, (iii) one business day after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited with an overnight courier service or (v) four
days after being deposited in the U.S. mail, First Class with postage prepaid and return receipt requested, and addressed to the parties at the addresses provided to the Company (which the Company agrees to disclose to the other parties upon
request) or such other address as a party may request by notifying the other in writing. 
 D. Successors. Any successor to the
Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree
expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term
“Company” shall include any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this section or which becomes bound by the terms of this Agreement by operation of law.
Subject to the restrictions on transfer set forth in this Agreement, this Agreement shall be binding upon Grantee and their heirs, executors, administrators, successors and assigns. 

E. Assignment; Transfers. Except as set forth in this Agreement, this Agreement, and any and all rights, duties and obligations
hereunder, shall not be assigned, transferred, delegated or sublicensed by the Grantee without the prior written consent of the Company. Any attempt by the Grantee without such consent to assign, transfer, delegate or sublicense any rights, duties
or obligations that arise under this Agreement shall be void. Except as set forth in this Agreement, any transfers in violation of any restriction upon transfer contained in any section of this Agreement shall be void, unless such restriction is
waived in accordance with the terms of this Agreement. 

  
 5 

 F. Waiver. Either party’s failure to enforce any provision of this Agreement shall
not in any way be construed as a waiver of any such provision, nor prevent that party from thereafter enforcing any other provision of this Agreement. The rights granted both parties hereunder are cumulative and shall not constitute a waiver of
either party’s right to assert any other legal remedy available to it. 
 G. Grantee Investment Representations and Further
Documents. The Grantee agree upon request to execute any further documents or instruments necessary or reasonably desirable in the view of the Company to carry out the purposes or intent of this Agreement, including (but not limited to) the
applicable exhibits and attachments to this Agreement. 
 H. Severability. Should any provision of this Agreement be found to be
illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable to the greatest extent permitted by law. 

I. Rights as Stockholder. Subject to the terms and conditions of this Agreement, Grantee shall have all of the rights of a stockholder
of the Company with respect to the Shares from and after the date that Grantee deliver a fully executed copy of this Agreement (including the applicable exhibits and attachments to this Agreement) and full payment for the Shares to the Company, and
until such time as Grantee dispose of the Shares in accordance with this Agreement. Upon such transfer, Grantee shall have no further rights as a holder of the Shares so purchased except (in the case of a transfer to the Company) the right to
receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and Grantee shall forthwith cause the certificate(s) evidencing the Shares so purchased to be surrendered to the Company for transfer or cancellation.

 J. Adjustment for Stock Split. All references to the number of Shares and the purchase price of the Shares in this Agreement shall
be adjusted to reflect any stock split, stock dividend or other change in the Shares which may be made after the date of this Agreement. 

K. Reliance on Counsel and Advisors. Grantee acknowledge that Wilson Sonsini Goodrich & Rosati, Professional Corporation, is
representing only the Company in this transaction. Grantee acknowledges that he or she has had the opportunity to review this Agreement, including all attachments hereto, and the transactions contemplated by this Agreement with his or her own legal
counsel, tax advisors and other advisors. Grantee are relying solely on his or her own counsel and advisors and not on any statements or representations of the Company or its agents for legal or other advice with respect to this investment or the
transactions contemplated by this Agreement. 
 L. Counterparts. This Agreement may be executed in one or more counterparts, each of
which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages shall be binding originals. 

(Signature page follows) 

  
 6 

 The parties represent that they have read this Agreement in its entirety, have had an opportunity
to obtain the advice of counsel prior to executing this Agreement and fully understand this Agreement. 
  

			
	COMPANY:
	
	UNITY BIOTECHNOLOGY, INC.
		
	By:	 	
                 

	Name:	 	Dr. Nathaniel E. David
	Title:	 	President and Chief Executive Officer

 [Signature Page to Restricted Stock Grant Agreement] 

 The parties represent that they have read this Agreement in its entirety, have had an opportunity
to obtain the advice of counsel prior to executing this Agreement and fully understand this Agreement. The Grantee agrees to notify the Company of any change in its address below. 

GRANTEE: 
 ASCENTAGE PHARMA GROUP CORP. LTD. 

Name: 
 Title: 

Address: 
 11/F, AXA Centre 

Gloucester Road, 
 Wanchai Hong Kong 

[Signature Page to Restricted Stock Grant Agreement] 

 EXHIBIT A 

INVESTMENT REPRESENTATION STATEMENT 
  

							
	 GRANTEE
	  	 	:	 	 	ASCENTAGE PHARMA GROUP CORP. LTD.
			
	 COMPANY
	  	 	:	 	 	UNITY BIOTECHNOLOGY, INC.
			
	 SECURITY
	  	 	:	 	 	COMMON STOCK
			
	 AMOUNT
	  	 	:	 	 	[•] SHARES
			
	 DATE
	  	 	:	 	 	[•]

  
  

In connection with the acquisition of the above-listed shares, I, each of the undersigned, represent to the Company as follows: 

1. The Company may rely on these representations. I understand that the Company’s sale of the shares to me has not
been registered under the Securities Act of 1933, as amended (the “Securities Act”), because the Company believes, relying in part on my representations in this document, that an exemption from such registration requirement is
available for such sale. I understand that the availability of this exemption depends upon the representations I am making to the Company in this document being true and correct. 

2. I am purchasing for investment. I am purchasing the shares solely for investment purposes, and not for further
distribution. My entire legal and beneficial ownership interest in the shares is being acquired and shall be held solely for my account, except to the extent I intend to hold the shares jointly with my spouse. I am not a party to, and do not
presently intend to enter into, any contract or other arrangement with any other person or entity involving the resale, transfer, grant of participation with respect to or other distribution of any of the shares. My investment intent is not limited
to my present intention to hold the shares for the minimum capital gains period specified under any applicable tax law, for a deferred sale, for a specified increase or decrease in the market price of the shares, or for any other fixed period in the
future. 
 3. I can protect my own interests. I can properly evaluate the merits and risks of an investment in the
shares and can protect my own interests in this regard, whether by reason of my own business and financial expertise, the business and financial expertise of certain professional advisors unaffiliated with the Company with whom I have consulted, or
my preexisting business or personal relationship with the Company or any of its officers, directors or controlling persons. 
 4. I am
informed about the Company. I am sufficiently aware of the Company’s business affairs and financial condition to reach an informed and knowledgeable decision to acquire the shares. I have had opportunity to discuss the plans,
operations and financial condition of the Company with its officers, directors or controlling persons, and have received all information I deem appropriate for assessing the risk of an investment in the shares. 

 5. I recognize my economic risk. I realize that the acquisition of the
shares involves a high degree of risk, and that the Company’s future prospects are uncertain. I am able to hold the shares indefinitely if required, and am able to bear the loss of my entire investment in the shares. 

6. I know that the shares are restricted securities. I understand that the shares are “restricted securities” in
that the Company’s sale of the shares to me has not been registered under the Securities Act in reliance upon an exemption for non-public offerings. In this regard, I also understand and agree that: 

A. I must hold the shares indefinitely, unless any subsequent proposed resale by me is registered under the Securities Act, or unless an
exemption from registration is otherwise available (such as Rule 144); 
 B. the Company is under no obligation to register any subsequent
proposed resale of the shares by me; and 
 C. the certificate evidencing the shares will be imprinted with a legend which prohibits
the transfer of the shares unless such transfer is registered or such registration is not required in the opinion of counsel for the Company. 

7. I am familiar with Rule 144. I am familiar with Rule 144 adopted under the Securities Act, which in some circumstances
permits limited public resales of “restricted securities” like the shares acquired from an issuer in a non-public offering. I understand that my ability to sell the shares under Rule 144 in the
future is uncertain, and may depend upon, among other things: (i) the availability of certain current public information about the Company; (ii) the resale occurring more than a specified period after my acquisition and full payment
(within the meaning of Rule 144) for the shares; and (iii) if I am an affiliate of the Company (A) the sale being made in an unsolicited “broker’s transaction”, transactions directly with a market maker or riskless principal
transactions, as those terms are defined under the Securities Exchange Act of 1934, as amended, (B) the amount of shares being sold during any three-month period not exceeding the specified limitations stated in Rule 144, and
(C) timely filing of a notice of proposed sale on Form 144, if applicable. 
 8. I know that Rule 144 may never be
available. I understand that the requirements of Rule 144 may never be met, and that the shares may never be saleable under the rule. I further understand that at the time I wish to sell the shares, there may be no public market for
the Company’s stock upon which to make such a sale, or the current public information requirements of Rule 144 may not be satisfied, either of which may preclude me from selling the shares under Rule 144 even if the relevant holding period had
been satisfied. 
 9. I know that I am subject to further restrictions on resale. I understand that in the event Rule
144 is not available to me, any future proposed sale of any of the shares by me will not be possible without prior registration under the Securities Act, compliance with some other registration exemption (which may or may not be available), or
each of the following: (i) my written notice to the Company containing detailed information regarding the proposed sale, (ii) my providing an opinion of my counsel to the effect that such sale will not require registration,

 
and (iii) the Company notifying me in writing that its counsel concurs in such opinion. I understand that neither the Company nor its counsel is obligated to provide me with any such
opinion. I understand that although Rule 144 is not exclusive, the Staff of the SEC has stated that persons proposing to sell private placement securities other than in a registered offering or pursuant to Rule 144 will have a substantial burden of
proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. 

10. I know that I may have tax liability due to the uncertain value of the shares. I understand that the Board of
Directors believes its valuation of the shares represents a fair appraisal of their worth, but that it remains possible that, with the benefit of hindsight, the Internal Revenue Service may successfully assert that the value of the shares on the
date of my acquisition is substantially greater than the Board’s appraisal. I understand that any additional value ascribed to the shares by such an IRS determination will constitute ordinary income to me as of the acquisition date, and that
any additional taxes and interest due as a result will be my sole responsibility payable only by me, and that the Company need not and will not reimburse me for that tax liability. 

11. Non-U.S. Investor. If I am not a United States person, I hereby represents that I am
satisfied as to the full observance of the laws of my jurisdiction in connection with any invitation to receive the shares issuable pursuant to this Agreement, or any use of this Agreement, including (i) the legal requirements within my
jurisdiction for the acquisition of the shares pursuant to this Agreement, (ii) any foreign exchange restrictions applicable to such receipt or transfer, (iii) any governmental or other consents that may need to be obtained and
(iv) the income tax and other tax consequences, if any, that may be relevant to the acquisition, holding, redemption, sale or transfer of such securities. My subscription for, and my continued beneficial ownership of the shares will not violate
any applicable securities or other laws of my jurisdiction. 
 12. Principal Place of Business. The address of my
principal place of business is set forth on the signature page below. 
 By signing below, the undersigned acknowledge their agreement with
each of the statements contained in this Investment Representation Statement as of the date first set forth above, and their intent for the Company to rely on such statements in issuing the shares to me. 

 

	
	ASCENTAGE PHARMA GROUP CORP. LTD.
	
	
                 

 Address of Grantee’ Principal Place of Business: 

11/F AXA Centre 
 Gloucester Road, Wanchai 

Hong KongEX-10.19(a)

 Exhibit 10.19(a) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 EXCLUSIVE LICENSE AGREEMENT 

This License Agreement (“Agreement”) is made as is made as of the 28th day of June, 2013 (the “Effective Date”) by and
between the Mayo Foundation for Medical Education and Research, having its principal place of business at 200 First Street SW, Rochester, MN 55905 (“Mayo”), and Cenexys, Inc., a Delaware corporation, having a place of business at 1700
Owens St., Suite 535, San Francisco, CA 94158 (“Company”). 
 BACKGROUND 

A.    Mayo owns certain Patent Rights and Know-How (each as defined below); 

B.    Company desires to obtain a license from Mayo to the Patent Rights and
Know-How, all on the terms and conditions set forth below; and 
 C.    Company
and Mayo further intend to enter into a Research Agreement pursuant to which Company will fund certain research conducted in the laboratories of Drs. Jan Van Deursen and James Kirkland at Mayo (the “Research Agreement”). 

D.    Company similarly intends to enter into a research agreement with the Buck Institute for Research on Aging
(“Buck Institute”) pursuant to which Company will fund certain research conducted in the laboratories of Dr. Judy Campisi (“Buck Research Agreement”) in exchange for the right to license any resulting inventions and certain
additional inventions of Buck Institute that exist as of the Effective Date (“Buck Inventions”) under a license agreement to be entered into by Company and Buck Institute (“Buck License Agreement”). 

NOW, THEREFORE, in consideration of the mutual covenants and promises herein contained, the parties hereto agree as follows: 

ARTICLE 1 

DEFINITIONS 
 As
used in this Agreement, the following capitalized terms shall have the meanings indicated: 
 1.1    “Additional
Inventions” shall mean discoveries and inventions that (i) are necessary or useful for the development, manufacture or commercialization of Licensed Products within the Field, and (ii) are developed in the laboratories of Drs. Jan
Van Deursen, James Kirkland and/or Darren Baker at Mayo during the IP Capture Period, excluding inventions generated pursuant to the Research Agreement and subject to the terms thereof. 

 1.2    “Affiliate” shall mean any entity which controls, is
controlled by or is under common control with Company. An entity shall be regarded as in control of another entity for purposes of this definition if it owns or controls more than fifty percent (50%) of the shares of the subject entity entitled
to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority). For Mayo, “Affiliate” shall mean any corporation or other entity within the same
“controlled group of corporations” as Mayo or its parent Mayo Clinic. For purposes of this definition, the term “controlled group of corporations” will have the same definition as Section 1563 of the Internal Revenue Code as
of November 10, 1998, but will include corporations or other entities which if not a stock corporation, more than fifty percent (50%) of the board of directors or other governing body of such corporation or other entity is controlled by a
corporation within the controlled group of corporations of Mayo or Mayo Clinic. Mayo’s Affiliates include, but are not limited to: Mayo Clinic; Mayo Collaborative Services, Inc.; Mayo Clinic - Methodist Hospital; Mayo Clinic - Saint Marys
Hospital; Mayo Clinic Florida; Mayo Clinic Arizona; and its Mayo Clinic Health System entities. 
 1.3    “Buck Know-how” shall mean unpatented technical information, know-how, processes, procedures, compositions, devices, methods, techniques, data or other subject matter that
is licensed to Company under the Buck License Agreement. 
 1.4    “Buck
Know-how Product” shall mean a product, composition or material for use in the Field that (a) incorporates Buck Know-How or whose discovery or
development was enabled by Company’s use of Buck Know-How and (b) is not a Buck Patent Product. 

1.5    “Buck Licensed Product” shall mean a Buck Patent Product or Buck
Know-How Product. 
 1.6    “Buck Patent Rights” shall mean
patent and patent applications exclusively licensed to Company under the Buck License Agreement. 
 1.7    “Buck
Patent Product” shall mean a product, composition, or material for use in the Field (i) the manufacture, sale or use of which would but for the license granted herein, infringe a Valid Claim of the Buck Patent Rights, or
(ii) whose discovery or development was enabled by Company’s use of a Buck Proprietary Research Tool (“Buck Tool Products”) 

1.8    “Buck Proprietary Research Tool” shall mean a Research Tool that has been designated as a
Proprietary Research Tool under the Buck License Agreement and exclusively licensed to Company. 
 1.9    “Buck
Proprietary Research Tool Patent” Buck Patent Rights claiming the Buck Proprietary Research Tools. 

1.10    “Field” shall mean the (a) prophylaxis , treatment, modulation or palliation of diseases or
conditions through (i) the clearance or killing of senescent cells, or (ii) the inhibition or modulation of the deleterious effects of senescent cells, and (b) the prediction, diagnosis, monitoring and tracking of diseases or
conditions being prevented, treated, modulated or inhibited pursuant to subsection (a) above. 

  
 -2- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.11    “IP Capture Period” shall mean the period commencing
on [***] and continuing until [***]. 
 1.12    “Know-How”
shall mean unpatented technical information, know-how, processes, procedures, compositions, devices, methods, techniques, data or other subject matter that is owned or controlled by Mayo that is useful for the
discovery, development or commercialization of Licensed Products. 

1.13    “Know-How Product” shall mean a product, composition or
material for use in the Field that (a) incorporates Know-How or whose discovery or development was enabled by Company’s use of Know-How and (b) is
not a Patent Product. 
 1.14    “Licensed Product” shall mean a Patent Product or Know-How Product. 
 1.15    “Licensed Subject Matter” shall mean the
Patent Rights and the Know-How. 
 1.16    “Net Sales” shall
mean the total amount invoiced to third parties on sales of Licensed Products by Company, its Affiliates, or Sublicensees, for which royalties are due under Article 3 below, less the following reasonable and customary deductions actually given:
(i) all trade, cash and quantity credits, discounts, refunds or government rebates; (ii) amounts for claims, allowances or credits for returns, retroactive price reductions, or chargebacks; (iii) packaging, handling fees and prepaid
freight, sales taxes, duties and other governmental charges (including value added tax) shown on the face of the invoice; and (iv) provisions for uncollectible accounts determined in accordance with US GAAP, consistently applied to all
products of the selling party, provided that in no event shall deductions for uncollectible accounts in any annual period exceed [***] percent ([***]%) of the cumulative Net Sales in such annual period. In the event that Company and a third
party enter into a barter transaction pursuant to which Company transfers Licensed Products to such third party in exchange for non-cash consideration provided in lieu of cash, then Net Sales shall be
calculated based on the value of the non-cash consideration received, provided that in no event shall the transferred Licensed Products be valued at more than the then-current customary sales price for such
Licensed Products invoiced to third parties or fair market value if there are no current invoices to third parties. For the removal of doubt, Net Sales shall not include sales by Company to its Affiliates for resale, provided that if Company
transfers Licensed Products to an Affiliate, and the Affiliate retransfers the Licensed Products to third-party purchaser, then Net Sales shall be the price charged by the Affiliate to third-party purchaser, less documented allowable deductions.

 In the event that Company grants a sublicense hereunder, and receives payments based upon the Sublicensee’s sales of Licensed
Products, Company may upon receiving consent from Mayo, which consent shall not be unreasonably withheld, substitute the definition of “Net Sales,” used by the Sublicensee to calculate payments to Company in place of the foregoing
definition of “Net Sales” for purposes of calculating royalties payable to Mayo on such Sublicensee’s sales. 

1.17    “Net Sublicensing Income” shall mean cash income (or any other consideration received in lieu of
a cash payment, including, without limitation, securities, materials and equipment) received from a Sublicensee in consideration of the grant to such Sublicensee of a 

  
 -3- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
sublicense under the Patent Rights, but excluding earned royalties and any other share of net sales (including revenue sharing and profit payments that would otherwise be reflected in net sales)
for the sale or distribution of Licensed Products. Net Sublicensing Income shall include without limitation any license signing fee, license maintenance fee, or milestone payment, and any consideration received for an investment in equity (and
conditional equity, such as warrants, convertible debt) of Company to the extent such consideration exceeds the fair market value of such equity or other conditional equity. Not included in the definition of Net Sublicensing Income is income
received by Company (a) as bona fide loans; (b) from equity investments (and conditional equity, such as warrants, convertible debt) in Company at market value; (c) as reimbursements for actual documented patent prosecution
costs and patent maintenance expenses; (d) as payment or reimbursement for research and development and/or other services conducted by or for Company, including costs of materials, equipment, manufacturing services or clinical testing, e.g.,
provided on the basis of full-time equivalent (“FTE”) efforts of personnel at or below commercially reasonable and standard FTE rates (“FTE Reimbursements”) and/or the reimbursement of out-of-pocket expenses; and (g) income to Company from a Sublicensee for commercial manufacturing of goods if such goods are intended for resale to third parties and the revenue derived from sales of
such goods will be treated as Net Sales and subject to an earned royalty due to Mayo. In addition, Company shall have the right to deduct from Net Sublicensing Income (i) withholding taxes and other taxes, duties and similar amounts owing with
respect to payments included within Net Sublicensing Income, but excluding what are commonly referred to as income taxes, and (ii) Eligible Expenses. As used herein, “Eligible Expenses” means (A) the documented costs and expenses
reasonably incurred by Company in performing responsibilities with respect to Licensed Products specifically in connection with a sublicense to the Patent Rights with a Sublicensee, including FTE Reimbursements and out of pocket costs, or in
performing research, development, and/or manufacture of Licensed Products in connection with such sublicense; and (B) a reasonable reserve for the costs and expenses that the Company has agreed to incur in a sublicense, but has not yet
incurred, in the performance of its responsibilities under such agreement with a Sublicensee (“Future Expenses”), provided that any estimated costs are clearly identified by Company and are accompanied by supporting documentation. 

1.18    “Patent Product” shall mean a product , composition, or material for use in the Field
(i) the manufacture, sale or use of which would but for the license granted herein, infringe a Valid Claim of the Patent Rights, or (ii) whose discovery or development was enabled by Company’s use of a Proprietary Research Tool
(“Tool Products”). 
 1.19    “Patent Rights” shall mean any and all rights in and to: 

(a)    all worldwide patent and patent applications claiming or disclosing subject matter claimed or disclosed in the
patent(s) and patent application(s) listed in Exhibit A hereto as of the Effective Date (the “Existing Patents”); 

(b)    all patents and patent applications claiming inventions developed pursuant to Research Agreement for which the
Company exercises its option thereunder (“Research Agreement Patents”); 

  
 -4- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c)    all patents and patent applications claiming Additional Inventions
with respect to which Company exercised its option pursuant to Section 2.2 (“Additional Invention Patents”); and 

(d)    all divisions, continuations,
continuations-in-part (but only for subject matter supported pursuant to 35 U.S.C. §112 by the foregoing) and substitutions of any of the patent applications in
(a)-(c) above, all patents issuing thereon, and all registrations, reissues, reexaminations or extensions of any kind with respect to any of the foregoing patents or their foreign counterparts. 

In the event that Mayo jointly owns an invention with the Company or a third party who works with the Company in the Field by reason of the fact that
personnel of Mayo, Company and/or such third party are joint inventors of such invention, it is understood that the Patent Rights include only Mayo’s rights as a joint owner of the patent applications and patents that claim such joint
invention. 
 1.20    “Permitted Third Party Funding Source” shall mean any non-profit or not-for-profit funding source that provides funding to the laboratories of Drs. Jan Van Deursen, James Kirkland and/or
Darren Baker. 
 1.21    “Proprietary Research Tool” shall mean a Research Tools(a) existing as of the
Effective Date and listed on Exhibit C, and (b) any future Research Tool used to discover or develop Patent Products and which Company elects to designate as a Proprietary Research Tool pursuant to Section 2.4. 

1.22    “Proprietary Research Tool Patents” shall mean the Patent Rights claiming the Proprietary
Research Tools. A list of the Proprietary Research Tool Patents existing as of the Effective Date and organized by the Proprietary Research Tool which they cover, is attached hereto as Exhibit C. 

1.23    “Research Tool” means animal models, cell lines, monoclonal antibodies, research assays and
reagents, cloning tools, and similar materials whose primary utility is in the conduct of basic scientific research.  

1.24    “Research Tool Patent Claim” shall mean a claim of a Research Agreement Patent or Additional
Invention Patent that claims a Research Tool that has not been designated as Proprietary Research Tool by Company pursuant to Section 2.4. 

1.25    “Sublicensee” shall mean any non-Affiliate third party to
whom Company has granted the right to manufacture and sell Licensed Products, with respect to Licensed Products made and sold by such third party. 

1.26    “Valid Claim” shall mean a claim of (a) an issued and unexpired patent which has not been
held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction and has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer
or otherwise; provided, however, that if the holding of such court or agency is later reversed by a court or agency with overriding authority, the claim shall be reinstated as a Valid Claim with respect to Net Sales made after the date of such
reversal, and (b) a claim of a 

  
 -5- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
pending patent application which has not been abandoned or finally rejected without the possibility of appeal or re-filing and has been pending for less
than thirteen (13) years from the filing date from which such claim takes priority, provided that in the event that a pending claim which has ceased to be a deemed a Valid Claim because it has been pending for more than thirteen (13) years
eventually issues, Company shall reimburse to Mayo for all back royalties (i.e., all royalties that would have been due during the period commencing on the date such pending claim ceased to be considered a Valid Claim and the date on which it
eventually issued), plus interest on such back royalties at the rate described in Section 3.13. 
 ARTICLE 2 

LICENSE 

2.1    Grant. Subject to the terms of the Agreement, Mayo hereby grants to Company a worldwide: (i) exclusive
license to all of Mayo’s interest in the Patent Rights (excluding the Research Tool Patent Claims) and the Proprietary Research Tools to develop, make, use, sell, offer for sale, import, export or otherwise distribute Licensed Products,
and (ii) nonexclusive license under the Research Tool Patent Claims and Know-How to develop, make, use, sell, offer for sale, import, export or otherwise distribute Licensed Products, and to have any of
the foregoing performed on its behalf by a third party. Notwithstanding any provisions in this Agreement, all rights granted in and to Additional Inventions under this Agreement will be subject to any and all obligations that Mayo may have to
Permitted Third Party Funding Sources 
 2.2    Option to Additional Inventions. 

(a)    Subject to the terms of this Agreement, Company shall have an option to include within the license granted to
Company under Section 2.1 above, all worldwide patent rights owned or controlled by Mayo with respect to Additional Inventions. 

(b)    Mayo shall notify Company promptly in writing of all Additional Inventions and shall provide Company with a
suitable description and other information reasonably requested by Company for the purpose of evaluating such Additional Inventions for purposes of its option (such notice and accompanying information, an “Invention Disclosure”). 

(c)    To exercise its option with respect to a particular Additional Invention, Company shall so notify Mayo within
ninety (90) days after receiving from Mayo a reasonably complete Invention Disclosure for such invention. Following such exercise, all patent applications and/or patents owned or controlled by Mayo directed to such invention shall be deemed
included within the Patent Rights. 
 2.3     Sublicenses. Company may grant and authorize sublicenses within the
scope of the license granted to Company pursuant to this Agreement. Each such sublicense shall include provisions: (a) substantially identical to Sections 2.5, 2.6 and 13.11 and Articles 10 and 11 with the Sublicensee in place of Company
and (b) that are not inconsistent with any terms herein. 

  
 -6- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2.4    Designation of Additional Proprietary Research Tools. 

(a)    Companyshall have the right upon written notice to Mayo to designate any Additional Invention that is a Research
Tool or any Research Tool arising under the Research Agreement as a Proprietary Research Tool, in which case all patents and patent applications owned or controlled by Mayo and directed to such Research Tool shall thereafter be deemed Proprietary
Research Tool Patents and such Research Tool, together with all patents and patent applications directed thereto, shall be exclusively licensed to Company. 

(b)    To exercise its option to designate a particular Research Tool as a Proprietary Research Tool, Company shall
provide Mayo with written notice of such election at the time it exercises its option under the Research Agreement or Section 2.2 above, as applicable, to include such Research Tool within the licenses granted to Company under Section 2.1
above. 
 2.5    Retained Rights. Mayo hereby retains a non-exclusive, non-transferrable right under the Licensed Subject Matter for its own clinical (including Mayo’s reference laboratory), educational and non-commercial research programs.

 2.6    Governmental Rights. All rights herein are subject to the rights and obligations to and requirements of
the U.S. government, if any have arisen or may arise, regarding the Patent Rights, including as set forth in 35 U.S.C. §§200 et al., 37 C.F.R. Part 401 et al. (“Bayh-Dole Act”). Company and Mayo each agree to comply with the
provisions of the Bayh-Dole Act as relevant to the Patent Rights, including in the case of Mayo, promptly reporting to the U.S. government all subject inventions and taking all actions necessary to take title to the Patent Rights, and in the case of
Company, promptly providing to Mayo with information reasonably requested by Mayo that is necessary to enable Mayo to meet its compliance requirements under the Bayh-Dole Act. 

2.7    No Implied Licenses. Nothing herein shall be construed as granting Company, by implication, estoppel or
otherwise, any license or other right to any intellectual property of Mayo other than the Licensed Subject Matter or to grant to Company any right or license other than those expressly granted herein. 

ARTICLE 3 
 PAYMENTS,
FUNDING OBLIGATIONS AND REPORTS 
 3.1    Equity. In consideration for the rights and licenses granted by
Mayo to Company herein and the research development support agreed to by Mayo under Section 3.11, Company shall, within thirty (30) days of the Effective Date and subject to Mayo’s execution and delivery to Company of a Stock Issuance
Agreement in substantially the form attached hereto as Exhibit B, issue to Mayo Two Million (2,000,000) shares of Company’s common stock. 

3.2    Minimum Annual Royalty Payments. As further consideration for the rights and licenses granted by Mayo to
Company herein Company shall pay to Mayo an annual minimum royalty of [***] U.S. Dollars ($[***]). The first annual minimum royalty payment shall be due within thirty (30) days of the fourth anniversary of the Effective Date with subsequent
annual minimum royalty payments being due within thirty (30) days of each subsequent anniversary of the Effective Date until the expiration (or if applicable, the earlier termination) of this Agreement.

  
 -7- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Annual minimum royalty payments shall be non-refundable but shall be creditable against milestones owed under Section 3.3, running royalties accrued
under Section 3.5 and/or sublicensing fees owed under Section 3.7, in each case during the one year period following the date on which such annual minimum royalty payment was paid. 

3.3    Development Milestone Payments. 

(a)    In consideration for the rights and licenses granted by Mayo to Company herein, Company agrees to pay Mayo following
payments upon the occurrence of each milestone specified below: 
  

			
	 Development Milestone Event
	  	Development Milestone Payment 
	 1. Commencement of a Phase I Clinical Study for a Licensed Product or a Buck Licensed
Product
	  	$[***]
		
	 2. Commencement of a Phase II Clinical Study for a Licensed Product or a Buck Licensed
Product
	  	$[***]
		
	 3. Commencement of a Phase III Clinical Study for a Licensed Product or a Buck Licensed
Product
	  	$[***]
		
	 4. Acceptance of filing of an MAA by the FDA, EMA or MHLW for a Licensed Product or a Buck
Licensed Product
	  	$[***]

 (b)    Development milestones 1 to 3 shall be payable once each for the first two products
(Licensed Products or Buck Licensed Products) to achieve the applicable milestone event. Milestone 4 shall be payable up to six times (i.e., once per MAA filed and accepted for review by the Regulatory Authority), for an aggregate of up to six
(6) payments total. For clarity, Company’s total payment obligations under this Section 3.3 shall in no event exceed [***] U.S. Dollars ($[***]) (i.e. up to an aggregate total of $[***] under milestones 1 to 3 and up to an aggregate
total of $[***] under milestone 4). 
 (c)    As used in this Section 3.3, the following terms shall have the
following meanings: 
 (i)    “EMA” means the European Medicines Agency or any successor agency
thereto; 
 (ii)    “FDA” means the United States Food and Drug Administration or any successor agency
thereto; 
 (iii)    “Phase I Clinical Study” means any study in humans the principal purpose of which
is preliminary determination of safety in healthy individuals or patients as described under 21 C.F.R. §312.21(a) with respect to the United States, or, with respect to a jurisdiction other than the United States, a similar clinical study, in
each case which shall be deemed commenced when the third participant in such study has received his or her initial dose of such Licensed Product or Buck Licensed Product; 

  
 -8- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (iv)    “Phase II Clinical Study” means a preliminary
efficacy and dose ranging human clinical study of a License Product in the target patient population, as described under 21 C.F.R. §312.21(b) with respect to the United States, or, with respect to a jurisdiction other than the United States, a
similar clinical study, in each case which shall be deemed commenced when the third patient in such study has received his or her initial dose of such Licensed Product or Buck Licensed Product; 

(v)    “Phase III Clinical Study” means a human clinical study designed as a pivotal study to confirm
with statistical significance the efficacy and safety of a Licensed Product or Buck Licensed Product with respect to a given indication, which study is performed for purposes of filing an MAA for such Product for such indication as described under
21 C.F.R. §312.21(c) with respect to the United States, or, with respect to a jurisdiction other than the United States, a similar clinical study, in each case which shall be deemed commenced when the third patient in such study has received
his or her initial dose of such Licensed Product or Buck Licensed Product; and 
 (vi)    “MAA”
(Marketing Approval Application) shall mean a new drug application filed with the FDA as more fully defined in 21 C.F.R. §314.50 et. seq., or similar application or submission filed with or submitted to any Regulatory Authority to obtain
permission to initiate marketing and sales of a Licensed Product or Buck Licensed Product for a particular indication. An MAA shall be deemed to be “accepted” if it has been accepted for substantive review by the FDA or other applicable
Regulatory Authority; 
 (vii)    “MHLW” means Japan’s Ministry of Health, Labor and Welfare
(also known as “Korosho”) or any successor agency thereto. 
 (viii)    “Regulatory
Authority” means a federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the discovery, development, commercialization or other use or
exploitation (including review and approval of MAAs) of pharmaceutical products in any jurisdiction, including the FDA, EMA, and the MHLW. 

(d)    Company agrees to promptly notify Mayo in writing of the occurrence of each of the foregoing milestones and the
payment for such milestone shall be due within thirty (30) days of occurrence thereof. 
 3.4    Sales
Milestones. In further consideration of the exclusive rights granted herein, Company shall pay Mayo the following milestone payments upon achievement of the corresponding sales milestones: 

(a)    Upon first achieving aggregate Net Sales of a Licensed Product or Buck Licensed Product equal to or exceeding [***]
U.S. Dollars ($[***]), Company shall pay Mayo [***] U.S. Dollars ($[***]); 

  
 -9- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b)    Upon first achieving aggregate Net Sales of a Licensed Product or Buck
Licensed Product equal to or exceeding [***] U.S. Dollars ($[***]), Company shall pay Mayo [***] U.S. Dollars ($[***]); 

(c)    Upon first achieving aggregate Net Sales of a Licensed Product or Buck Licensed Product equal to or exceeding [***]
U.S. Dollars ($[***]), Company shall pay Mayo [***] U.S. Dollars ($[***]); 
 (d)    Upon first achieving aggregate Net
Sales of a Licensed Product or Buck Licensed Product equal to or exceeding [***] U.S. Dollars ($[***]), Company shall pay Mayo [***] U.S. Dollars ($[***]). 

The foregoing sales milestones shall be payable once for each of the first two products (Licensed Products or Buck Licensed Products) to
achieve the applicable sales thresholds. For clarity, Company’s total payment obligations under this Section 3.4 shall in no event exceed [***] U.S. Dollars ($[***]). Company agrees to promptly notify Mayo in writing of the occurrence of
each of the foregoing milestones and the payment for such milestone shall be included with the royalty payment due for the calendar quarter in which such sales milestone was achieved. 

3.5    Earned Royalty. As additional consideration of the rights and licenses granted by Mayo to Company herein,
except as otherwise provided in this Article 3, Company agrees to pay to Mayo as running royalties a percentage of Net Sales from Licensed Products and Buck Licensed Products sold by Company, its Affiliates and Sublicensees as follows: 

(a)    [***]% of (i) annual Net Sales of Know-How Products and (ii) of
annual net sales of Buck Know-How Products; 
 (b)    For Patent Products and
Buck Patent Products for which there are no Valid Claims within the Patent Rights or Buck Patent Rights covering the composition of matter of the applicable Licensed Product or Buck Licensed Product: 

 

			
	 Annual Net Sales of Licensed
Product
	  	Applicable Royalty Rate
	 Portion of worldwide annual Net Sales of such Patent Products and Buck Patent Products less than
or equal to [***] Dollars (US$[***])
	  	[***]%
	 Portion of worldwide annual Net Sales of such Patent Products and Buck Patent Products over [***]
Dollars (US$[***])
	  	[***]%

 (c)    For Patent Products and Buck Patent Products for which there is at least one Valid
Claim within the Patent Rights covering the composition of matter of the applicable Patent Product or Buck Patent Product: 
  

			
	 Annual Net Sales of Licensed
Product
	  	Applicable Royalty Rate
	 Portion of worldwide annual Net Sales of such Patent Products and Buck Patent Products less than
or equal to [***] Dollars (US$[***])
	  	[***]%

  
 -10- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	
Annual Net Sales of Licensed Product
	  	Applicable Royalty Rate
	 Portion of worldwide annual Net Sales of such Patent Products and Buck Patent Products over [***]
Dollars (US$[***])
	  	[***]%

 Licensed Products or Buck Licensed Products transferred to Mayo or its Affiliates are not considered transfers for purposes of
determining Net Sales or for calculating Earned Royalty. No Earned Royalty is due to Mayo on transfers to Mayo or its Affiliates. 

3.6    Certain Additional Terms. 

(a)    Royalty Term. 

(i)    Mayo’s right to receive royalties under Section 3.5(c) above shall expire on a product-by-product basis in a particular country upon the expiration of the last to expire Valid Claim in the Licensed Patents covering the composition of matter of such
Licensed Product in such country (or in the case of the Buck Licensed Patents, upon the expiration of the last to expire Valid Claim in the Buck Licensed Patents covering the composition of matter of such Buck Licensed Product in such country). 

(ii)    Mayo’s right to receive royalties under Section 3.5(b) above shall expire on a product-by-product basis in a particular country upon the expiration of the last to expire Valid Claim in the Licensed Patents covering such Licensed Product in such country
(or in the case of the Buck Licensed Patents, upon the expiration of the last to expire Valid Claim in the Buck Licensed Patents covering such Buck Licensed Product in such country), provided that with respect to any Patent Product that is a Tool
Product (or any Buck Patent Product that is a Tool Patent), Mayo shall be entitled to continue to receive a royalty under Section 3.5(b) with respect to worldwide sales of such Patent Product or Buck Patent Product until the expiration of the
last to expire Valid Claim of the Tool Patent(s) covering the Proprietary Research Tool(s) (or until the expiration of the last to expire Valid Claim of the Buck Tool Patent(s) covering the Buck Proprietary Research Tool(s)), in each case whose use
enabled the discovery or development of such Patent Product or Buck Patent Product. 
 (iii)    Mayo’s right to
receive royalties under Section 3.5(a) above shall expire on earlier of (A) the thirteenth (13th) anniversary of the first commercial sale of the first Licensed Product or Buck Licensed
Product by Company anywhere in the world, or (B) January 1, 2037. 
 (b)    Single Royalty; Non-Royalty Sales. In the event that a Licensed Product or Buck Licensed Product would be subject to two or more of the royalty provisions in Sections 3.5 above (e.g., in the event a Licensed Product or Buck
Licensed Product is covered by multiple Valid Claims, some of which are composition of matter claims and some of which are not), only a single royalty shall be paid to Mayo with respect to such Licensed Product or Buck Licensed Product, that royalty
being the highest of the royalties applicable to such Licensed Product or Buck Licensed Product. It is understood that royalties under Section 3.5(c) shall only be payable with respect to Licensed Products or Buck Licensed Products whose sale
would infringe a Valid Claim of the Licensed Patents or Buck Licensed Patents covering the composition of matter of such Licensed Product or 

  
 -11- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Buck Licensed Product in the country for which such Licensed Product or Buck Licensed Product is sold. In no event shall more than one royalty be due hereunder with respect to any Licensed
Product (or Buck Licensed Product) unit; nor shall a royalty be payable under this Article 3 with respect to sales of Licensed Products or Buck Licensed Products at cost for use in research and/or development, in clinical trials or as samples.

 (c)    Multiple Royalties. If Company, its Affiliate or Sublicensee is required to pay a non-Affiliate third party other than the Buck Institute for Research on Aging amounts with respect to a Licensed Product or Buck Licensed Product under agreements for patent rights or other technologies which
Company, its Affiliate or Sublicensee, in its best judgment, determines are necessary to license or acquire with respect to such Licensed Product or Buck Licensed Product, Company may deduct such amount owing to such
non-Affiliate third parties (prior to any reductions) from the royalty owing to Mayo for the sale of such Licensed Product or Buck Licensed Product pursuant to Section 3.5 above. Notwithstanding the
foregoing provisions of this Section 3.6, in no event shall the royalties due to Mayo pursuant to Section 3.5 above be so reduced to an amount less than: 

(i)    [***] percent ([***]%) of the amount that would otherwise be due to Mayo with respect to Licensed Products or Buck
Licensed Product subject to Sections 3.5(a) or 3.5(b); or 
 (ii)    [***] percent ([***]%) of the amount that would
otherwise be due to Mayo with respect to Licensed Products or Buck Licensed Product subject to Section 3.5(c). 

(d)    Royalties on Buck Licensed Products. Notwithstanding anything to the contrary in this Agreement it is
understood and agreed that any given Buck Licensed Product shall only be subject to milestone and royalty obligations under this Agreement if that product is subject to milestone and royalty obligations under the Buck License Agreement. 

3.7    Sublicense Fees. 

(a)    Company shall pay to Mayo [***]% of the Net Sublicensing Income received by Company or its Affiliates 

(b)    Notwithstanding the foregoing: 

(i)    Company shall only be obligated to share [***]% of that portion of the Net Sublicensing Income that exceeds the
then current aggregate amount spent by Company on the development of the Licensed Products included in such sublicense as of the date such Net Sublicensing Income was received; and 

(ii)    Company’s total payment obligations under this Section 3.7 shall be capped at [***] U.S. Dollars
($[***]). 

  
 -12- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 3.8    Records & Accounting. Company will
throughout the Term, keep complete, true and accurate books of accounts and records of Net Sales sufficient to support and verify the calculation of all royalties and sales milestones due and payable to Mayo under this Agreement. Such books and
records will be open at reasonable times, but not more frequently than once per calendar year, for inspection by a representative of Mayo, at Mayo’s expense, for audit and verification of any report required under this Agreement with respect to
Net Sales received not more than ten (10) years prior to the date of Mayo’s request. Mayo representative will treat as confidential all relevant matters and will be a person or firm reasonably acceptable to Company. In the event such audit
reveals an underpayment to Mayo, Company will within thirty (30) days pay the royalty due in excess of the royalty actually paid. In the event the audit reveals an underpayment by Company of more than [***] percent ([***]%) of the amount due,
Company will pay interest on the royalty due in excess of the royalty actually paid in accordance with Section 3.13 below and will also pay all of Mayo’s costs in conducting the audit. Notwithstanding the foregoing, in the event that it is
demonstrated that Company has knowingly underpaid royalties owed to Mayo (other than royalties being withheld by Company in connection with a dispute between the parties pre-dating the audit), Company will pay
Mayo interest on the royalty due in excess of the royalty actually paid at the maximum interest rate allowed by law in the State of New York. 

3.9    Reports. Beginning with the first accrual of Net Sales on which a royalty is due hereunder, Company shall
provide to Mayo a quarterly royalty report as follows: Within ninety (90) days after the end of each calendar quarter, Company shall deliver to Mayo a true and accurate report, giving such particulars of the business conducted by Company, its
Affiliates and Sublicensees, if any, during such calendar quarter as are pertinent to account for royalties due under this Article 3. Such report shall include at least (i) the total of Net Sales during such quarter; (ii) the calculation
of royalties; and (iii) the total royalties so calculated and due to Mayo. Simultaneously with the delivery of each such report, Company shall pay to Mayo the total royalties, if any, due to Mayo for the period of such report. If no royalties
are due, Company shall so report. Mayo shall not provide to non-Affiliate third parties any information contained in reports provided to Mayo under this Section 3.09, or learned by Mayo under
Section 3.08 above. 
 3.10    Payments. All amounts payable hereunder by Company shall be payable in United
States Dollars. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rates used by Company in calculating Company’s own revenues for financial
reporting purposes. 
 3.11    Research & Development Funding by Mayo. Subject to the
terms and conditions of this Agreement, Mayo agrees to provide a total of up to [***] Dollars in two tranches of [***] Dollars ($[***]) each towards conducting research and development beneficial to and approved by the Sponsor, which Sponsor has
agreed to use to fund research at Mayo. Sponsor shall be permitted to satisfy its payment obligation to Mayo through the use of a convertible promissory note (which note shall be convertible into Series A Preferred Stock of the
Sponsor). Parties shall jointly develop the protocols of such research and development program. 

3.12    Taxes. Company is responsible for all taxes, duties, import duties, assessments and other governmental
charges, however designated, which are now or hereafter imposed by any authority on Company related to manufacture, use, sale or importation of the Licensed Product. Mayo shall be responsible for paying any and all taxes (other than withholding
taxes or deduction of 

  
 -13- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
tax at source required by applicable law to be paid by Company) levied on it by account of its receipt of any payments it receives under this Agreement. If applicable laws require that taxes be
withheld or deducted at source from any amounts due to Mayo under this Agreement, Company shall (a) deduct these taxes from the remittable amount, (b) pay the taxes to the proper taxing authority, and (c) deliver to Mayo a statement
including the amount of tax withheld and justification therefor, and such other information as may be necessary for tax credit purposes. Company will obtain, or assist Mayo in obtaining, any tax reduction (including avoidance of double taxation),
tax refund or tax exemption available to Mayo by treaty or otherwise. 
 3.13    Overdue Payments. If overdue,
the payments due under this Agreement shall bear interest until paid at a per annum rate of [***] percent ([***]%) above the prime rate in effect at US Bank on the due date. The acceptance of any payment, including such interest, shall not foreclose
Mayo from exercising any other right or seeking any other remedy that it may have as a consequence of the failure of Company to make any payment when due. 

ARTICLE 4 
 DATA
ACCESS 
 Promptly after the Effective Date, Mayo shall, upon Company’s request, provide to Company all data, reports, analyses
and other information in its possession or control relating to the Licensed Products. Thereafter, upon request by Company, Mayo shall provide copies of all such additional materials as have been generated since the prior disclosure. Subject to the
provisions of Article 6 below, Company will have the right to use all such data and materials for any purpose, and to provide the same to third parties under reasonable conditions of confidentiality or as Company considers appropriate in connection
with obtaining regulatory approval to market and/or commercializing Licensed Products. In addition, as reasonably requested by Company from time to time, Mayo shall at Company’s sole expense (reimbursing Mayo’s costs to make and deliver
such Proprietary Research Tools), deliver to Company reasonable quantities of Proprietary Research Tools based on availability. The Parties agree that any and all materials supplied to Company by Mayo shall be supplied under a material transfer
agreement, the terms of which shall be substantially similar to the template material transfer agreement attached hereto as Exhibit D. 

ARTICLE 5 
 DUE
DILIGENCE 
 5.1    Obligation to Exploit. Company shall use commercially reasonable efforts to bring one
or more Licensed Products to market and to meet the market demand therefor. 
 5.2     Reports. Within sixty
(60) days following the end of each calendar year during the term of this Agreement, Company shall prepare and deliver to Mayo a written report which shall describe, in reasonable detail, the research performed during the previous year
employing the Licensed Subject Matter, the progress of the development and exploitation of Licensed Subject Matter during the previous year and the names of all Sublicensees (if any), including which of the Sublicensees are Affiliates Subject to the
parameters outlined in Section 3.8. 

  
 -14- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ARTICLE 6 

CONFIDENTIALITY 

6.1    Confidential Information. Except as provided herein, each party shall maintain in confidence, and shall not
use for any purpose or disclose to any third party, non-public and proprietary information disclosed by the other party that (a) if in written, graphic, machine readable or other tangible form is marked
“Confidential,” “Proprietary” or in some other manner to indicate its confidential nature, and if disclosed in oral or other intangible form is designated as confidential at the time of its initial disclosure and is confirmed in
writing as confidential within forty-five (45) days following such disclosure, or (b) that, given the nature of the information or the circumstances surrounding its disclosure, reasonably should be considered as confidential (collectively,
“Confidential Information”). Confidential Information shall not include any information that is: (i) already known to the receiving party at the time of disclosure hereunder, or (ii) now or hereafter becomes publicly known other
than through acts or omissions of the receiving party, or (iii) is disclosed to the receiving party by a third party under no obligation of confidentiality to the disclosing party or (iv) independently developed by the receiving party
without reliance on the Confidential Information of the disclosing party. 
 6.2    Permitted Usage.
Notwithstanding the provisions of Section 6.1 above, the receiving party may use or disclose Confidential Information of the disclosing party to the extent necessary to exercise its rights hereunder (including commercialization and/or
sublicensing of Licensed Subject Matter) or fulfill its obligations and/or duties hereunder and in filing for, prosecuting or maintaining any proprietary rights, prosecuting or defending litigation, complying with applicable governmental regulations
and/or submitting information to tax or other governmental authorities; provided that if the receiving party is required by law to make any public disclosures of Confidential Information of the disclosing party, to the extent it may legally do so,
it will give reasonable advance notice to the disclosing party of such disclosure and will use its reasonable efforts to secure confidential treatment of Confidential Information prior to its disclosure (whether through protective orders or
otherwise). For clarity, to the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, a party may disclose Confidential Information of the other to Sublicensees, consultants, and
outside contractors on the condition that each such entity receiving such Confidential Information agrees to obligations of confidentiality and non-use at least as stringent as those therein. 

ARTICLE 7 
 PATENTS
AND INVENTIONS 
 7.1    Prosecution of Patent Rights. Company shall responsible for directing and
controlling the filing, prosecution and maintenance of all Patent Rights. Company shall select the patent attorney, who is reasonably acceptable to Mayo. Mayo shall have full rights of consultation with the patent attorney so selected on all matters
relating to Patent Rights. For purposes of this Article 7, “prosecution and maintenance” of patents and patent applications shall be deemed to include, without limitation, the conduct of interferences or oppositions, and/or requests for re-examinations, reissues or extensions of patent terms. 

  
 -15- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 7.2    Patent Costs. Company acknowledges and agrees that the license
granted hereunder is in partial consideration for Company’s assumption of the costs of prosecution and maintenance of the Patent Rights as described herein. Company agrees to pay and shall pay for all expenses incurred in connection with the
prosecution and maintenance of the Patent Rights. If Company fails to pay the expenses incurred pursuant to Section 7.1 with respect to one or patents or patent applications, Mayo may, at its sole discretion, terminate Company’s license
with respect to such patent or patent applications, or with Company’s written consent, convert it into a non-exclusive license. If at any time Company determines that it no longer desires to pay the
patent costs with respect to one or more patents or patent applications within the Patent Rights, Company shall give sixty (60) days advance written notice to Mayo. Upon such notice, Company’s license with respect to such patent or patent
application shall terminate and Company shall not be obligated to pay for any corresponding patent costs incurred after the end of such sixty (60) day period (but shall remain responsible for all patent costs incurred prior to and during such
sixty (60) day period). 
 ARTICLE 8 

TERM AND TERMINATION 

8.1    Term. Unless terminated earlier pursuant to this Article 8, the term of this Agreement shall commence
on the Effective Date and continue in full force and effect until the happening of the latter of: (1) the expiration, revocation or invalidation of the last issued Valid Claim within the Patent Rights or the abandonment or rejection of the last
pending Valid Claim within the Patent Rights, whichever is later, or (2) the expiration of thirteen (13) years after first commercial sale of the first Licensed Product. Upon its natural expiration (and not upon earlier termination), the
rights under the Agreement shall convert into a fully paid-up License that grants Company the right to continue selling Licensed Products. 

8.2    Termination for Breach. 

(a)    In the event of a material breach of this Agreement, the non-breaching party
shall be entitled to terminate this Agreement by written notice to the breaching party, if such breach is not cured within ninety (90) days after written notice is given by the nonbreaching party to the breaching party specifying the breach.

 (b)    Notwithstanding Section 8.2(a), in the event of a bonafide good faith dispute regarding whether in
fact a breach has occurred (other than a dispute regarding an alleged breach by Company of Article 11 (Use of Names), which for clarity shall not be subject to the following), if the party alleged to be in breach of a material obligation or
provision of this Agreement disputes such breach within the applicable ninety (90) day period, the parties shall submit the dispute to a single arbitrator from the American Arbitration Association (“AAA”) for a preliminary, non-binding determination, within sixty (60) days of the submission of the matter to arbitration, as to whether it was more likely than not that a material obligation or provision of this Agreement was
breached. Such arbitration shall be conducted in New York City in the State of New York pursuant to the commercial arbitration rules of the AAA, as modified by the procedures set forth in this Section 8.2(b). The arbitrator shall be selected by
mutual agreement of the parties; provided, 

  
 -16- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
however, that if the parties cannot agree on an arbitrator within five days of a party’s request for a determination under this Section 8.2(b) as to whether a breach of a material
obligation or provision of this Agreement has occurred, the arbitrator shall be selected by the AAA. If the arbitrator determines that it is more likely than not that the asserted breach was a breach of a material obligation or provision of this
Agreement and the breaching party fails to cure such alleged breach within thirty (30) days after such determination, the non-breaching party may terminate this Agreement forthwith by written notice to
the other party. If on the other hand, the arbitrator determines that it is more likely than not that the asserted breach was not a breach of a material obligation or provision of this Agreement, the
non-breaching party shall not have the right to terminate this Agreement unless and until it has been finally determined by a court of competent jurisdiction that a material obligation or provision of this
Agreement has been breached and the breaching party fails to cure such breach within thirty (30) days after such determination. It is understood that a determination by the arbitrator in accordance with this Article 8.2(a) will not be
binding on the parties as to whether the disputed activity was in fact a breach of a material obligation or provision of this Agreement and shall apply only to determine whether or not the cure period should be tolled as provided in this
Article 8.2(a). In any case, a final determination of whether a breach of a material obligation or provision of this Agreement has occurred shall be determined only by a court of competent jurisdiction. 

8.3    Termination by Company. Any provision herein notwithstanding, Company may terminate this Agreement, in its
entirety or as to any particular patent or patent application within the Patent Rights, or as to any particular Licensed Product, at any time by giving Mayo at least sixty (60) days prior written notice. From and after the effective date of a
termination under this Section 8.3 with respect to a particular patent or application, such patent(s) and patent application(s) in the particular country shall cease to be within the Patent Rights for all purposes of this Agreement, and all
rights and obligations of Company with respect to such patent(s) and patent application(s) shall terminate. From and after the effective date of a termination under this Section 8.3 with respect to a particular Licensed Product, the license
granted under Section 2.1 above shall terminate with respect to such Licensed Product, and the same shall cease to be a Licensed Product for all purposes of this Agreement. Upon a termination of this Agreement in its entirety under this
Section 8.3, all rights and obligations of the parties shall terminate, except as provided in Section 8.4 below. 

8.4    Survival. 

(a)    Termination of this Agreement for any reason shall not release either party hereto from any liability which at the
time of such termination has already accrued to the other party. 
 (b)    In the event this Agreement is terminated for
any reason, Company shall provide Mayo with a written inventory of all Licensed Products that Company and its Affiliates have in process of manufacture, in use or in stock and Company and its Affiliates shall have the right to sell or otherwise
dispose of such Licensed Products, all subject to the payment to Mayo royalties pursuant to Article 3 hereof. 

  
 -17- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c)    Upon termination of this Agreement by Mayo for any reason, any
sublicense granted by Company hereunder shall survive, provided that upon request by Mayo, such Sublicensee promptly agrees in writing to be bound by the applicable terms of this Agreement. 

(d)    Articles 6 (Confidentiality), 10 (Indemnification and Insurance), 11 (Use of Names), Section 8.4 (Survival),
12.3 (Disclaimers) and 13.11 (Limitation of Liability) shall survive the expiration and any termination of this Agreement. Except as otherwise provided in this Article 8, all rights and obligations of the parties under this Agreement shall terminate
upon the expiration or termination of this Agreement. 
 ARTICLE 9 

INFRINGEMENT 

9.1    Enforcement. If either party determines that a third party is making, using or selling a product that may
infringe the Patent Rights, that party shall notify the other party in writing. 
 (a)    Company shall have the first
right (itself or through others), at its sole option, to bring suit to enforce the Patent Rights, and/or to defend any declaratory judgment action with respect thereto, in each case with respect to the manufacture, sale or use of a product within
the Field; provided, however, that Company shall keep Mayo reasonably informed as to the defense and/or settlement of such action. Mayo shall have the right to participate in any such action with counsel of its own choice at its own expense. All
recoveries received by Company from an action to enforce the Patent Rights shall be first applied to reimburse Company’s and then Mayo’s unreimbursed expenses, including without limitation, reasonable attorney’s fees and court costs.
Any remainder shall, to the extent the same pertains to an infringement of the Patent Rights, be divided [***] percent ([***]%) to Company and [***] percent ([***]%) to Mayo, provided that Mayo’s portion shall not exceed the amount Mayo would
have received as a royalty hereunder if the infringing activities had been made by Company. 
 (b)    In the event
Company elects not to initiate an action to enforce the Patent Rights against infringement by a third party within the Field, within one (1) year of a request by Mayo to do so, (or within such shorter period which may be required to preserve
the legal rights of Mayo under the laws of the relevant government), Mayo may initiate such action at its expense with Company’s consent, which consent shall not be unreasonably withheld. Company shall have the right to participate in any such
action with counsel of its own choice at its own expense. All recoveries received by Mayo from an action to enforce the Patent Rights shall be first applied to reimburse Mayo’s and then Company’s unreimbursed expenses, including without
limitation, reasonable attorney’s fees and court costs. Any remainder shall, to the extent the same pertains to an infringement of the Patent Rights in the Field, be divided [***] percent ([***]%) to Company and [***] percent ([***]%) to Mayo.

 9.2    Defense. If Company, its Affiliate, Sublicensee, distributor or other customer is sued by a third party
charging infringement of patent rights that dominate a claim of the Patent Rights or that cover other Related Material with respect to the manufacture, use, distribution or sale of a 

  
 -18- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Licensed Product, Company will promptly notify Mayo. As between the parties to this Agreement, Company will be entitled to control the defense in any such action(s) and withhold [***] percent
([***]%) of the royalties related to such Licensed Product otherwise payable to Mayo and use the withheld royalties to reimburse the legal defense costs, attorneys’ fees and liability incurred in such infringement suit(s). Notwithstanding the
foregoing, Company agrees to withhold only that portion of such royalties as may reasonably be necessary to reimburse amounts in accordance with this Section 9.2. For clarity, if Company is required to pay a royalty or other amounts to a third
party to make and/or sell a Licensed Product as a result of a final judgment or settlement; such amounts may be deducted from the running royalties payable to Mayo hereunder in accordance with Section 3.6(c) above. 

9.3    Cooperation. In any suit, action or other proceeding in connection with enforcement and/or defense of the
Patent Rights, Mayo shall reasonably cooperate, including without limitation, by executing such documents as Company may reasonably request. Upon the request of and, at the sole expense of Company, Mayo shall make available at reasonable times and
under appropriate conditions all relevant personnel, records, papers, information, samples, specimens and other similar materials in Mayo’s possession. In the absence of an agreement to institute a suit jointly, Mayo shall not be required to
join such action unless it has agreed to do so in writing prior to the commencement thereof, or unless deemed by the court as a necessary party. Company will bear the entire cost of such litigation, including attorneys’ fees. 

9.4    No Implied Obligations. Except as expressly provided in this Article 9, neither party has any obligation to
bring or prosecute actions or suits against any third party for patent infringement. 
 ARTICLE 10 

INDEMNIFICATION & INSURANCE 

10.1    Company shall hold harmless and indemnify Mayo, its trustees, directors, officers, employees, agents and the
successor and assigns of any of the foregoing (collectively, the “Indemnitees”), and hold each Indemnitee harmless from and against any and all losses, costs, expenses, damages and liabilities resulting from claims, actions, demands,
judgments, suits or proceedings brought by third parties (including, without limitation, reasonable attorneys’ fees and other expenses of litigation) (any of the foregoing, a “Claim”), regardless of the legal theory asserted, against
any Indemnitee, arising from or occurring as a result of: (a) the exercise or practice by Company or its Affiliates or Sublicensees of the rights and licenses granted under this Agreement, and (b) the research, development, design,
manufacture, distribution, use, sale, importation, exportation or other disposition of Licensed Products by Company or its Affiliates or Sublicensees; except and to the extent that such Claim(s) arise from or are related to a breach by Mayo of any
of its representations or warranties in Section 12.1. Any Indemnitee that intends to claim indemnification under this Article 10 shall: (i) promptly notify Company in writing of any Claim with respect to which the Indemnitee intends
to claim such indemnification, (ii) give Company sole control of the defense and/or settlement thereof, and (iii) provide Company, at Company’s expense, with reasonable assistance and full information reasonably available to Mayo

  
 -19- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
with respect to such Claim. Company shall not settle any claim, suit or proceeding subject to this Article 10 or otherwise consent to an adverse judgment in such claim, suit or proceeding if the
same materially diminishes the rights or interests of the Indemnitee without the express written consent of the Indemnitee. Notwithstanding the foregoing, Company shall have no obligations for any Claim if the Indemnitee seeking indemnification
makes any admission, settlement or other communication regarding such Claim (unless made truthfully under a circumstance that legally requires such act by Mayo, in which case Mayo shall use its best efforts to inform Company of such of its intent to
make such admission prior to making it) without the prior written consent of Company, which consent shall not be unreasonably withheld 

10.2    Insurance. 

(a)    No later than sixty (60) days following the Effective Date, Company will obtain, keep in force and maintain
general liability insurance with minimum coverage limits of at least [***] U.S. Dollars (US $[***]). 
 (b)    No later
than sixty (60) days prior the initiation of the first human clinical testing of the first Licensed Product, Company will obtain, keep in force and maintain occurrence-based liability insurance, including contractual liability, with minimum
coverage limits of at least [***] U.S. Dollars (US $[***]), 
 (c)    No later than sixty (60) days prior the first
commercial sale of the first Licensed Product, Company will obtain, keep in force and maintain occurrence-based liability insurance, including products liability and contractual liability, in an amount and for a time period sufficient to cover the
liability assumed by Company hereunder during the Term and after, such amount being at least [***] U.S. Dollars (US $[***]) . 

(d)    Company’s policies will name Mayo and its Affiliates as additional-named insureds. The minimum limits of any
insurance coverage required herein shall not limit Company’s liability. 
 ARTICLE 11 

USE OF NAMES 

Except as required by law or in the normal course of business identification, neither Company nor Mayo shall issue any press release or other
written statements in connection with this Agreement intended for use in the public media in a manner suggesting any endorsement by the other of Company or Mayo respectively, without the approval of such other party. Company will not use for
publicity, promotion or other purpose, any logo, name, trade name, service mark or trademark of Mayo or its Affiliates, including, but not limited to, the terms “Mayo®,” “Mayo
Clinic®” and the triple shield Mayo logo, or any simulation, abbreviation or adaptation of the same, or the name of any Mayo employee or agent, without Mayo’s prior, written, express
consent. With regard to the use of Mayo’s name, all requests for approval pursuant to this Section must be submitted to the Mayo Clinic Public Affairs Business Relations Group, at the following e-mail
address: PublicAffairsBR@Mayo.edu at least ten (10) business days prior to the date on which a response is needed. 

  
 -20- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ARTICLE 12 

REPRESENTATIONS AND WARRANTIES 

12.1    Representations & Warranties by Mayo. (a) Mayo has the sole right and authority
to enter into this Agreement and grant the rights and licenses hereunder; (b) Mayo has not previously granted any rights under the Licensed Subject Matter or Proprietary Research Tools to any third party and will not grant any rights in the
Proprietary Research Tools and Patent Rights (other than Research Tool Patent Claims with respect to Research Tools that Company has declined to designate as Proprietary Research Tools) to any third party during the term of this Agreement (it being
understood that some Licensed Subject Matter and Proprietary Research Tools may be co-owned by third parties and Mayo makes no representations as to how such third parties may have disposed of their rights in
such co-owned Licensed Subject Matter and Proprietary Research Tools); (c) to the best of the knowledge of Mayo Clinic Ventures (“MCV”), which is the business unit of Mayo that is in-charge of intellectual property protection and commercialization, there are no claims of third parties as of the Effective Date that would call into question the rights of Mayo to grant to Company the rights
contemplated hereunder; and (d) to the best of MCV’s knowledge, except for the Patent Rights, as of the Effective Date, Mayo does not own or control any patent or patent application (including any invention disclosure or draft patent
application for which a patent application is intended to be filed) the claims of which would dominate any practice of the Licensed Subject Matter. 

12.2    Representations & Warranties by Company. Company warrants and represents to Mayo
that: 
 (a)    it has independently evaluated the Patent Rights, Know-How and
Proprietary Research Tools and their applicability or utility in Company’s activities, and Company is entering into this Agreement on the basis of its own evaluation of such applicability or utility and not in reliance of any representation by
Mayo with respect thereto, and assumes all risk and liability in connection with such determination; 
 (b)     it will
obtain and maintain insurance coverage as set forth in Section 10.2; 
 (c)     the execution and delivery of this
Agreement has been duly authorized and no further approval, corporate or otherwise, is required in order to execute this binding Agreement; 

(d)     it shall comply and require its Sublicensees to comply with all applicable international, national and state laws,
ordinances and regulations in its performance under this Agreement; and 
 (e)     its rights and obligations under this
Agreement do not conflict with any contractual obligation or court or administrative order by which it is bound. 

  
 -21- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 12.3    Disclaimers. 

(a)    EXCEPT AS PROVIDED IN THIS ARTICLE 12, NEITHER PARTY MAKES ANY WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY
OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER HEREOF. 
 (b)    EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT,
NEITHER PARTY MAKES ANY PROMISES, COVENANTS, GUARANTEES, REPRESENTATIONS OR WARRANTIES OF ANY NATURE, DIRECTLY OR INDIRECTLY, EXPRESS, STATUTORY OR IMPLIED, INCLUDING WITHOUT LIMITATION IN THE CASE OF MAYO, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, SUITABILITY, DURABILITY, CONDITION, QUALITY OR ANY OTHER CHARACTERISTIC OF THE PATENT RIGHTS, KNOW-HOW OR CONFIDENTIAL INFORMATION. SUBJECT TO THE TERMS, REPRESENTATIONS AND WARRANTIES
EXPRESSLY PROVIDED IN THIS AGREEMENT, PATENT RIGHTS, KNOW-HOW AND CONFIDENTIAL INFORMATION ARE PROVIDED “AS IS.” SUBJECT TO COMPANY’S RIGHTS AT LAW OR IN EQUITY TO SEEK REDRESS FOR ANY BREACH BY
MAYO OF THE REPRESENTATIONS AND WARRANTIES EXPRESSLY PROVIDED BY MAYO IN THIS AGREEMENT, COMPANY EXPRESSLY WAIVES ALL RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST MAYO FOR MISREPRESENTATION OR FOR BREACH OF GUARANTEE, REPRESENTATION OR WARRANTY OF
ANY KIND RELATING TO THE PATENT RIGHTS, KNOW-HOW OR CONFIDENTIAL INFORMATION. MAYO EXPRESSLY DISCLAIMS ANY IMPLIED WARRANTIES ARISING FROM ANY COURSE OF DEALING, USAGE OR TRADE PRACTICE, WITH RESPECT TO: THE
SCOPE, VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS, KNOW-HOW AND CONFIDENTIAL INFORMATION; THAT ANY PATENT WILL ISSUE BASED UPON ANY PENDING PATENT APPLICATION; OR THAT THE USE, SALE, OFFER FOR SALE OR
IMPORTATION OF THE PATENT RIGHTS, KNOW-HOW OR MATERIALS WILL NOT INFRINGE OTHER INTELLECTUAL PROPERTY RIGHTS. WITHOUT LIMITING MAYO’S OBLIGATIONS UNDER SECTION 9.3 ABOVE TO COOPERATE WITH COMPANY WITH
RESPECT TO ENFORCEMENT OF THE PATENT RIGHTS, NOTHING IN THIS AGREEMENT WILL BE CONSTRUED AS AN OBLIGATION FOR MAYO TO BRING, PROSECUTE OR DEFEND ACTIONS REGARDING THE PATENT RIGHTS, KNOW-HOW AND CONFIDENTIAL
INFORMATION. 
 ARTICLE 13 

GENERAL 

13.1    Patent Marking. Company agrees to mark, and require its Affiliates and Sublicensees to mark, all Licensed
Products sold with all applicable patent numbers or otherwise conform to patent laws and practices of the country in which such Licensed Product is sold. 

13.2    No Implied Obligations. Company’s sole obligation to exploit the Licensed Subject Matter is as set
forth in Articles 5. Nothing in this Agreement shall be deemed to require Company to otherwise exploit the Licensed Subject Matter nor prevent Company from commercializing products similar to or competitive with a Licensed Product. 

  
 -22- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 13.3    Independent Contractors. The relationship of Mayo and Company
established by this Agreement is that of independent contractors. Nothing in this Agreement shall be construed to create any other relationship between Mayo and Company. Neither party shall have any right, power or authority to assume, create or
incur any expense, liability or obligation, express or implied, on behalf of the other. 
 13.4    Confidential
Terms. Except as expressly provided herein, each party agrees not to disclose any terms of this Agreement to any third party without the consent of the other party, except as required by securities or other applicable laws, to prospective and
other investors and such party’s accountants, attorneys and other professional advisors. 

13.5    Assignment. This Agreement may not be assigned by Company without the prior written consent of Mayo, except
to a party that succeeds to all or substantially all of Company’s business or assets relating to this Agreement whether by sale, merger, operation of law or otherwise; provided that such assignee or transferee promptly agrees in writing to be
bound by the terms and conditions of this Agreement. Mayo may assign its right to receive payments hereunder upon prior written notice to Company. 

13.6    Force Majeure. In the event either party hereto is prevented from or delayed in the performance of any of
its obligations hereunder by reason of acts of God, war, strikes, riots, storms, fires, or any other cause whatsoever beyond the reasonable control of the party, the party so prevented or delayed shall be excused from the performance of any such
obligation to the extent and during the period of such prevention or delay. 
 13.7    Notices. Any notice or
other communication required by this Agreement shall be made in writing and given by prepaid, first class, certified mail, return receipt requested, and shall be deemed to have been served on the date received by the addressee at the following
address or such other address as may from time to time be designated to the other party in writing: 
  

			
	If to Mayo:	  	Mayo Foundation for Medical Education and Research
		  	Mayo Clinic Ventures – BB4
		  	200 First Street SW
		  	Rochester, MN 55905-0001
		  	Attn: [***]
		  	Phone: [***]
		  	Facsimile: [***]
		  	Email: [***]
		
	If to Company:	  	Cenexys, Inc.
		  	1700 Owens St., Suite 535,
		  	San Francisco, CA 94158
		  	Attn: [***]
		  	Phone: [***]
		  	Email: [***]

  
 -23- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
		
	with a copy to:	  	Wilson Sonsini Goodrich & Rosati
		  	650 Page Mill Road
		  	Palo Alto, California 94304-1050
		  	Attn: [***]

 13.8    Compliance with Law. Company shall comply with all applicable federal,
state and local laws and regulations in connection with its activities pursuant to this Agreement. 

13.9    Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the
laws of the State of New York, without reference to its principles of conflicts of law. 
 13.10    No Waiver. A
waiver, express or implied, by either Mayo or Company of any right under this Agreement or of any failure to perform or breach hereof by the other party hereto shall not constitute or be deemed to be a waiver of any other right hereunder or of any
other failure to perform or breach hereof by such other party, whether of a similar or dissimilar nature thereto. 

13.11    Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR ANY
SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE)
OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. IN NO EVENT WILL MAYO’S LIABILITY OF ANY KIND INCLUDE ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE LOSSES OR
DAMAGES, EVEN IF MAYO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR EXCEED THE TOTAL COMPENSATION THAT HAS ACTUALLY BEEN PAID TO MAYO BY COMPANY AS OF THE DATE OF FILING AN ACTION AGAINST MAYO THAT RESULTS IN THE SETTLEMENT OR AWARD OF
DAMAGES TO COMPANY. 
 13.12    Headings. Headings included herein are for convenience only, do not form a part
of this Agreement and shall not be used in any way to construe or interpret this Agreement. 

13.13    Severability. If any provision of this Agreement shall be found by a court to be void, invalid or
unenforceable, the same shall be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of the remainder of this Agreement. 

13.14    Entire Agreement. This Agreement constitutes the entire understanding and agreement between the parties
with respect to the subject matter hereof and supersedes any and all prior negotiations, representations, agreements, and understandings, written or oral, that the parties may have reached with respect to the subject matter hereof. No agreements
altering or 

  
 -24- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
supplementing the terms hereof may be made except by means of a written document signed by the duly authorized representatives of each of the parties hereto. It is understood that the Research
Agreement is separate and independent from this Agreement and termination of either agreement shall not operate to terminate or otherwise effect the rights and obligations of the parties under the other agreement. 

13.15    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original,
but both of which together shall constitute one and the same instrument, and photocopy, facsimile, electronic or other copies shall have the same effect for all purposes as an inked original. Each party hereto consents to be bound by photocopy,
electronic or facsimile signatures of each party’s representative hereto. 

  
 -25- 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to
execute this Agreement. 
  

									
	 Mayo Foundation for Medical Education
	 		 	 Cenexys, Inc.

	 and Research
	 		 	(“Company”)
	(“Mayo”)	 		 		 	
					
	By:	 	
/s/ Daniel D. Estes               
                                         
        
	 		 	By:	 	 /s/ Nathaniel David

	Name:	 	 Daniel D. Estes
	 		 	Name:	 	 Nathaniel David

	Title:	 	 Assistant Treasurer
	 		 	Title:	 	 CEO

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 

PATENT RIGHTS 

[***] 

  
 Exhibit A-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT B 

STOCK PURCHASE AGREEMENT 

CENEXYS, INC. 
 STOCK
PURCHASE AGREEMENT 
 This Stock Purchase Agreement (the “Agreement”) is made as of
[                    , 2013] by and between Cenexys, Inc., a Delaware corporation (the “Company”), and Mayo Foundation for
Medical Education and Research (the “Purchaser”). 
 In consideration of the mutual covenants and representations
set forth below, the Company and the Purchaser agree as follows: 
 1.    Purchase and Sale of the Shares.
Subject to the terms and conditions of this Agreement, the Company agrees to sell to the Purchaser and the Purchaser agrees to purchase from the Company on the Closing (as defined below) 2,000,000 shares of the Company’s Common Stock, par value
$0.0001 per share (the “Shares”), at a price of $0.006 per share (the “Purchase Price”), for an aggregate purchase price of $12,000.00. 

2.    Closing. The purchase and sale of the Shares shall occur at a closing (the “Closing”)
to be held on the date first set forth above, or at any other time mutually agreed upon by the Company and the Purchaser. The Closing will take place at the principal office of the Company or at such other place as shall be designated by the
Company. At the Closing, the Purchaser shall deliver the aggregate Purchase Price set forth above to the Company by wire transfer, check or any other method of payment permissible under applicable law and approved by the Company’s board of
directors (or any combination of such methods of payment), and the Company will issue, as promptly thereafter as practicable, a stock certificate, registered in the name of the Purchaser, reflecting the Shares. 

3.    Limitation on Payments. 

A.    Payments Limitation. In the event that the severance and other benefits provided for in this
Agreement or otherwise payable to the Purchaser (i) constitute “parachute payments” within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the
“Excise Tax”), then the Purchaser’s benefits under this Agreement shall be either 

(1)    delivered in full, or 

(2)    delivered as to such lesser extent which would result in no portion of such benefits being subject to the Excise
Tax, 
 whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the
receipt by the Purchaser on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code. Any reduction
in payments and/or benefits required by this Section 3 will occur in the following order: (1) reduction of cash payments; (2) reduction of vesting acceleration of 

  
 Exhibit B-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
equity awards; and (3) reduction of other benefits paid or provided to Purchaser. In the event that acceleration of vesting of equity awards is to be reduced, such acceleration of vesting
will be cancelled in the reverse order of the date of grant for Purchaser’s equity awards. If two or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis.
In no event will Purchaser exercise any discretion with respect to the ordering of any reductions of payments or benefits under this Section 3. 

B.    Determination. Unless the Company and the Purchaser otherwise agree in writing, any
determination required under this Section 3 shall be made in writing by the Company’s independent public accountants or a national “Big Four” accounting firm selected by the Company (the “Accountants”),
whose determination shall be conclusive and binding upon the Purchaser and the Company for all purposes. For purposes of making the calculations required by this Section 3, the Accountants may make reasonable assumptions and approximations
concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. The Company and the Purchaser shall furnish to the Accountants such information and documents as
the Accountants may reasonably request in order to make a determination under this Section 3. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 3. 

4.    Restrictions on Transfer. 

A.    Investment Representations and Legend Requirements. The Purchaser hereby makes the investment
representations listed on Exhibit A to the Company as of the date of this Agreement and as of the date of the Closing, and agrees that such representations are incorporated into this Agreement by this reference, such that the Company may rely
on them in issuing the Shares. The Purchaser understands and agrees that the Company shall cause the legends set forth below, or substantially equivalent legends, to be placed upon any certificate(s) evidencing ownership of the Shares, together with
any other legends that may be required by the Company or by applicable state or federal securities laws: 
 THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL
SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT. 
 THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER, A RIGHT OF FIRST REFUSAL, A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING AND A REPURCHASE OPTION HELD BY THE ISSUER
OR ITS ASSIGNEE(S) AS SET FORTH IN THE STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL, LOCK-UP PERIOD AND REPURCHASE OPTION ARE BINDING ON TRANSFEREES OF THESE SHARES. 

  
 Exhibit B-2 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 B.    Stop-Transfer Notices. The Purchaser agrees that
to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate
notations to the same effect in its own records. 
 C.    Refusal to Transfer. The Company
shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or
pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 
 D.    Lock-Up Period. The Purchaser hereby agrees that the Purchaser shall not sell, offer, pledge, contract to sell, grant any option or contract to purchase, purchase any option or contract to sell, grant
any right or warrant to purchase, lend or otherwise transfer or encumber, directly or indirectly, any Shares or other securities of the Company, nor shall the Purchaser enter into any swap, hedging or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company, during the period from the filing of the first registration statement of the Company filed under the Securities Act of 1933, as
amended (the “Securities Act”), that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act through the end of the
180-day period following the effective date of such registration statement (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i) the
publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions
or amendments thereto). The Purchaser further agrees, if so requested by the Company or any representative of its underwriters, to enter into such underwriter’s standard form of “lockup” or “market standoff” agreement in a
form satisfactory to the Company and such underwriter. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of any such restriction period. 

E.    Shares. No Shares purchased pursuant to this Agreement, nor any beneficial interest in such
Shares, shall be sold, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by the Purchaser or any subsequent transferee, other than in compliance with the Company’s right of first refusal
provisions contained in Section 5 of this Agreement. 
 5.    Company’s Right of First
Refusal. Before any Shares acquired by the Purchaser pursuant to this Agreement (or any beneficial interest in such Shares) may be sold, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by
the Purchaser or any subsequent transferee (each a “Holder”), such Holder must first offer such Shares or beneficial interest to the Company and/or its assignee(s) as follows: 

A.    Notice of Proposed Transfer. The Holder shall deliver to the Company a written notice stating:
(i) the Holder’s bona fide intention to sell or otherwise transfer the Shares; (ii) the name of each proposed transferee; (iii) the number of Shares to be transferred to each proposed transferee; (iv) the bona
fide cash price or other consideration for which the Holder proposes to transfer the Shares; and (v) that by delivering the notice, the Holder offers all such Shares to the Company and/or its assignee(s) pursuant to this section and on the
same terms described in the notice. 
 B.    Exercise of Right of First Refusal. At any time within
30 days after receipt of the Holder’s notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the
proposed transferees, at the purchase price determined in accordance with Section 5.C. 

  
 Exhibit B-3 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 C.    Purchase Price. The purchase price for the Shares
purchased by the Company and/or its assignee(s) under this section shall be the price listed in the Holder’s notice. If the price listed in the Holder’s notice includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the board of directors of the Company in its sole discretion. 

D.    Payment. Payment of the purchase price shall be made, at the option of the Company and/or its
assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company and/or its assignee(s), or by any combination thereof within 30 days after receipt by the Company of the Holder’s
notice (or at such later date as is called for by such notice). 
 E.    Holder’s Right to
Transfer. If all of the Shares proposed in the notice to be transferred to a given proposed transferee are not purchased by the Company and/or its assignee(s) as provided in this section, then the Holder may sell or otherwise transfer
such Shares to that proposed transferee; provided that: (i) the transfer is made only on the terms provided for in the notice, with the exception of the purchase price, which may be either the price listed in the notice or any higher
price; (ii) such transfer is consummated within 60 days after the date the notice is delivered to the Company; (iii) the transfer is effected in accordance with any applicable securities laws, and if requested by the Company, the Holder
shall have delivered an opinion of counsel acceptable to the Company to that effect; and (iv) the proposed transferee agrees in writing to receive and hold the Shares so transferred subject to all of the provisions of this Agreement, including
but not limited to this section, and there shall be no further transfer of such Shares except in accordance with the terms of this section. If any Shares described in a notice are not transferred to the proposed transferee within the period provided
above, then before any such Shares may be transferred, a new notice shall be given to the Company, and the Company and/or its assignees shall again be offered the right of first refusal described in this section. 

F.    Involuntary Transfers. Subject to the other provisions of this Section 5, in the event, at any
time after the date of this Agreement, of any transfer by operation of law or other involuntary transfer (including, but not limited to, transfers by operation of law or other involuntary transfers in connection with a divorce, dissolution, legal
separation or annulment) of all or a portion of the Shares by the record holder thereof that does not occur in accordance with the other provisions of this Section 5, the Company shall have the right to purchase all of the Shares transferred at
the greater of the purchase price paid by Purchaser pursuant to this Agreement or the fair market value of the Shares on the date of transfer (as determined by the board of directors of the Company). Upon such a transfer, the persons transferring or
acquiring the Shares shall promptly notify the Secretary of the Company in writing of such transfer. The right to purchase such Shares shall be provided to the Company for a period of 30 days following receipt by the Company of written notice
of the transfer. 
 G.    Exception for Certain Family Transfers. Notwithstanding anything to the
contrary contained elsewhere in this section, the transfer of any or all of the Shares during the Holder’s lifetime (except in connection with a divorce, dissolution, legal separation or annulment) or on the Holder’s death by will or
intestacy to (i) the Holder’s spouse or domestic partner; (ii) the Holder’s lineal descendants or antecedents, siblings, aunts, uncles, nieces and nephews (including adoptive relationships and step relationships), and their
spouses or domestic partners; and (iv) a trust or other similar estate planning vehicle for the benefit of the Holder or any such person, shall be exempt from the provisions of this section; provided that, in each such case, the
transferee agrees in writing to receive and hold the Shares so transferred subject to all of the provisions of this Agreement, including but not limited to this section, and there shall be no further transfer of such Shares except in accordance with
the terms of this section; and provided further, that without the prior written consent of the Company, which may be withheld in the sole discretion of the Company, no more than three transfers may be made pursuant to this

  
 Exhibit B-4 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
section, including all transfers by the Holder and all transfers by any transferee. For purposes of this Agreement, a person will be deemed to be a “domestic partner” of
another person if the two persons (1) reside in the same residence and plan to do so indefinitely, (2) have resided together for at least one year, (3) are each at least 18 years of age and mentally competent to consent to contract,
(4) are not blood relatives any closer than would prohibit legal marriage in the state in which they reside, (5) are financially interdependent, as demonstrated to the reasonable satisfaction of the Company and (6) have each been the
sole spouse equivalent of the other for the year prior to the transfer and plan to remain so indefinitely; provided that a person will not be considered a domestic partner if he or she is married to another person or has any other spouse
equivalent. 
 H.    Termination of Right of First Refusal. The rights contained in this section
shall terminate as to all Shares purchased hereunder upon the earlier of: (i) the closing date of the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the
Securities and Exchange Commission under the Securities Act, and (ii) the closing date of a Change of Control pursuant to which the holders of the outstanding voting securities of the Company receive securities of a class registered pursuant to
Section 12 of the Securities Exchange Act of 1934, as amended. 
 6.    Tax Consequences. The Purchaser has
reviewed with the Purchaser’s own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. The Purchaser is relying solely on such advisors and not on any
statements or representations of the Company or any of its agents. The Purchaser understands that the Purchaser (and not the Company) shall be responsible for any tax liability that may arise as a result of the transactions contemplated by this
Agreement. 
 7.    General Provisions. 

A.    Choice of Law. This Agreement shall be governed by the internal substantive laws, but not the
choice of law rules, of California. 
 B.    Integration. This Agreement, including all exhibits
hereto, represents the entire agreement between the parties with respect to the purchase of the Shares by the Purchaser and supersedes and replaces any and all prior written or oral agreements regarding the subject matter of this Agreement
including, but not limited to, any representations made during any interviews, relocation discussions or negotiations whether written or oral. 

C.    Notices. Any notice, demand, offer, request or other communication required or permitted to be
given by either the Company or the Purchaser pursuant to the terms of this Agreement shall be in writing and shall be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one business day
after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited with an overnight courier service or (v) four days after being deposited in the U.S. mail, First Class with
postage prepaid and return receipt requested, and addressed to the parties at the addresses provided to the Company (which the Company agrees to disclose to the other parties upon request) or such other address as a party may request by notifying
the other in writing. 
 D.    Successors. Any successor to the Company (whether direct or indirect
and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under
this Agreement in the same manner and to the same extent as the 

  
 Exhibit B-5 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any successor to the
Company’s business and/or assets which executes and delivers the assumption agreement described in this section or which becomes bound by the terms of this Agreement by operation of law. Subject to the restrictions on transfer set forth in this
Agreement, this Agreement shall be binding upon the Purchaser and his or her heirs, executors, administrators, successors and assigns. 

E.    Assignment; Transfers. Except as set forth in this Agreement, this Agreement, and any and all rights,
duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by the Purchaser without the prior written consent of the Company. Any attempt by the Purchaser without such consent to assign, transfer, delegate or
sublicense any rights, duties or obligations that arise under this Agreement shall be void. Except as set forth in this Agreement, any transfers in violation of any restriction upon transfer contained in any section of this Agreement shall be void,
unless such restriction is waived in accordance with the terms of this Agreement. 
 F.    Waiver.
Either party’s failure to enforce any provision of this Agreement shall not in any way be construed as a waiver of any such provision, nor prevent that party from thereafter enforcing any other provision of this Agreement. The rights granted
both parties hereunder are cumulative and shall not constitute a waiver of either party’s right to assert any other legal remedy available to it. 

G.    Purchaser Investment Representations and Further Documents. The Purchaser agrees upon request
to execute any further documents or instruments necessary or reasonably desirable in the view of the Company to carry out the purposes or intent of this Agreement, including (but not limited to) the applicable exhibits and attachments to this
Agreement. 
 H.    Severability. Should any provision of this Agreement be found to be illegal or
unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable to the greatest extent permitted by law. 

I.    Rights as Stockholder. Subject to the terms and conditions of this Agreement, the Purchaser
shall have all of the rights of a stockholder of the Company with respect to the Shares from and after the date that the Purchaser delivers a fully executed copy of this Agreement (including the applicable exhibits and attachments to this Agreement)
and full payment for the Shares to the Company, and until such time as the Purchaser disposes of the Shares in accordance with this Agreement. Upon such transfer, the Purchaser shall have no further rights as a holder of the Shares so purchased
except (in the case of a transfer to the Company) the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and the Purchaser shall forthwith cause the certificate(s) evidencing the Shares so
purchased to be surrendered to the Company for transfer or cancellation. 
 J.    Adjustment for Stock
Split. All references to the number of Shares and the purchase price of the Shares in this Agreement shall be adjusted to reflect any stock split, stock dividend or other change in the Shares which may be made after the date of this
Agreement. 
 K.    Employment at Will. THE PURCHASER
ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THIS AGREEMENT IS EARNED ONLY BY CONTINUING SERVICE AS A SERVICE PROVIDER AT WILL (AND NOT THROUGH THE ACT OF BEING HIRED OR PURCHASING SHARES HEREUNDER). THE PURCHASER FURTHER
ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A 

  
 Exhibit B-6 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
SERVICE PROVIDER FOR THE VESTING PERIOD, OR FOR ANY PERIOD AT ALL, AND SHALL NOT INTERFERE WITH THE PURCHASER’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE PURCHASER’S
RELATIONSHIP WITH THE COMPANY AT ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE.    /s/ DE 7-3-13 

L.    Arbitration and Equitable Relief. 

(1)    Arbitration. IN CONSIDERATION OF THE PROMISES IN THIS AGREEMENT, THE PURCHASER AGREES THAT ANY AND ALL
CONTROVERSIES, CLAIMS, OR DISPUTES WITH ANYONE (INCLUDING THE COMPANY AND ANY EMPLOYEE, OFFICER, DIRECTOR, SHAREHOLDER OR BENEFIT PLAN OF THE COMPANY IN THEIR CAPACITY AS SUCH OR OTHERWISE) ARISING OUT OF, RELATING TO, OR RESULTING FROM THIS
AGREEMENT, SHALL BE SUBJECT TO BINDING ARBITRATION UNDER THE ARBITRATION RULES SET FORTH IN CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 1280 THROUGH 1294.2, INCLUDING SECTION 1283.05 (THE “RULES”) AND PURSUANT TO
CALIFORNIA LAW. DISPUTES WHICH THE PURCHASER AGREES TO ARBITRATE, AND THEREBY AGREES TO WAIVE ANY RIGHT TO A TRIAL BY JURY, INCLUDE ANY STATUTORY CLAIMS UNDER STATE OR FEDERAL LAW, INCLUDING, BUT NOT LIMITED TO, CLAIMS UNDER TITLE VII OF THE CIVIL
RIGHTS ACT OF 1964, THE AMERICANS WITH DISABILITIES ACT OF 1990, THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, THE OLDER WORKERS BENEFIT PROTECTION ACT, THE WORKER ADJUSTMENT AND RETRAINING NOTIFICATION ACT, THE CALIFORNIA FAIR EMPLOYMENT AND
HOUSING ACT, THE FAMILY AND MEDICAL LEAVE ACT, THE CALIFORNIA FAMILY RIGHTS ACT, THE CALIFORNIA LABOR CODE, CLAIMS OF HARASSMENT, DISCRIMINATION OR WRONGFUL TERMINATION AND ANY STATUTORY CLAIMS. THE PURCHASER FURTHER UNDERSTANDS THAT THIS AGREEMENT
TO ARBITRATE ALSO APPLIES TO ANY DISPUTES THAT THE COMPANY MAY HAVE WITH THE PURCHASER. 
 (2)    Procedure. THE
PURCHASER AGREES THAT ANY ARBITRATION WILL BE ADMINISTERED BY THE AMERICAN ARBITRATION ASSOCIATION (“AAA”) AND THAT THE NEUTRAL ARBITRATOR WILL BE SELECTED IN A MANNER CONSISTENT WITH ITS NATIONAL RULES FOR THE RESOLUTION OF
EMPLOYMENT DISPUTES. THE PURCHASER AGREES THAT THE ARBITRATOR SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY PARTY TO THE ARBITRATION, INCLUDING MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION AND MOTIONS TO DISMISS AND DEMURRERS, PRIOR
TO ANY ARBITRATION HEARING. THE PURCHASER ALSO AGREES THAT THE ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES, INCLUDING ATTORNEYS’ FEES AND COSTS, AVAILABLE UNDER APPLICABLE LAW. PURCHASER UNDERSTANDS THAT THE COMPANY WILL PAY FOR ANY
ADMINISTRATIVE OR HEARING FEES CHARGED BY THE ARBITRATOR OR AAA EXCEPT THAT PURCHASER SHALL PAY THE FIRST $125.00 OF ANY FILING FEES ASSOCIATED WITH ANY ARBITRATION PURCHASER INITIATES. PURCHASER AGREES THAT THE ARBITRATOR SHALL ADMINISTER AND
CONDUCT ANY ARBITRATION IN A MANNER CONSISTENT WITH THE RULES AND THAT TO THE EXTENT THAT THE AAA’S NATIONAL RULES FOR THE RESOLUTION OF EMPLOYMENT DISPUTES CONFLICT WITH THE RULES, THE RULES SHALL TAKE PRECEDENCE. THE PURCHASER AGREES THAT THE
DECISION OF THE ARBITRATOR SHALL BE IN WRITING. 

  
 Exhibit B-7 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (3)    Remedy. EXCEPT AS PROVIDED BY THE RULES AND THIS AGREEMENT,
ARBITRATION SHALL BE THE SOLE, EXCLUSIVE AND FINAL REMEDY FOR ANY DISPUTE BETWEEN THE PURCHASER AND THE COMPANY. ACCORDINGLY, EXCEPT AS PROVIDED FOR BY THE RULES AND THIS AGREEMENT, NEITHER THE PURCHASER NOR THE COMPANY WILL BE PERMITTED TO PURSUE
COURT ACTION REGARDING CLAIMS THAT ARE SUBJECT TO ARBITRATION. NOTWITHSTANDING, THE ARBITRATOR WILL NOT HAVE THE AUTHORITY TO DISREGARD OR REFUSE TO ENFORCE ANY LAWFUL COMPANY POLICY, AND THE ARBITRATOR SHALL NOT ORDER OR REQUIRE THE COMPANY TO
ADOPT A POLICY NOT OTHERWISE REQUIRED BY LAW WHICH THE COMPANY HAS NOT ADOPTED. 
 (4)    Availability of Injunctive
Relief. BOTH PARTIES AGREE THAT ANY PARTY MAY PETITION A COURT FOR INJUNCTIVE RELIEF AS PERMITTED BY THE RULES INCLUDING, BUT NOT LIMITED TO, WHERE EITHER PARTY ALLEGES OR CLAIMS A VIOLATION OF ANY CONFIDENTIAL INFORMATION OR INVENTION
ASSIGNMENT AGREEMENT BETWEEN THE PURCHASER AND THE COMPANY OR ANY OTHER AGREEMENT REGARDING TRADE SECRETS, CONFIDENTIAL INFORMATION, NONSOLICITATION OR LABOR CODE §2870. BOTH PARTIES UNDERSTAND THAT ANY BREACH OR THREATENED BREACH OF SUCH AN
AGREEMENT WILL CAUSE IRREPARABLE INJURY AND THAT MONEY DAMAGES WILL NOT PROVIDE AN ADEQUATE REMEDY THEREFOR AND BOTH PARTIES HEREBY CONSENT TO THE ISSUANCE OF AN INJUNCTION. IN THE EVENT EITHER PARTY SEEKS INJUNCTIVE RELIEF, THE PREVAILING PARTY
SHALL BE ENTITLED TO RECOVER REASONABLE COSTS AND ATTORNEYS’ FEES. 
 (5)    Administrative Relief. THE
PURCHASER UNDERSTANDS THAT THIS AGREEMENT DOES NOT PROHIBIT THE PURCHASER FROM PURSUING AN ADMINISTRATIVE CLAIM WITH A LOCAL, STATE OR FEDERAL ADMINISTRATIVE BODY SUCH AS THE DEPARTMENT OF FAIR EMPLOYMENT AND HOUSING, THE EQUAL EMPLOYMENT
OPPORTUNITY COMMISSION OR THE WORKERS’ COMPENSATION BOARD. THIS AGREEMENT DOES, HOWEVER, PRECLUDE THE PURCHASER FROM PURSUING COURT ACTION REGARDING ANY SUCH CLAIM. 

(6)    Voluntary Nature of Agreement. THE PURCHASER ACKNOWLEDGES AND AGREES THAT THE PURCHASER IS EXECUTING THIS
AGREEMENT VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE BY THE COMPANY OR ANYONE ELSE. THE PURCHASER FURTHER ACKNOWLEDGES AND AGREES THAT THE PURCHASER HAS CAREFULLY READ THIS AGREEMENT AND THAT THE PURCHASER HAS ASKED ANY QUESTIONS NEEDED
FOR THE PURCHASER TO UNDERSTAND THE TERMS, CONSEQUENCES AND BINDING EFFECT OF THIS AGREEMENT AND FULLY UNDERSTANDS IT, INCLUDING THAT THE PURCHASER IS WAIVING THE PURCHASER’S RIGHT TO A JURY TRIAL. FINALLY, THE
PURCHASER AGREES THAT THE PURCHASER HAS BEEN PROVIDED AN OPPORTUNITY TO SEEK THE ADVICE OF AN ATTORNEY OF THE PURCHASER’S CHOICE BEFORE SIGNING THIS AGREEMENT. 

M.    Reliance on Counsel and Advisors. The Purchaser acknowledges that Wilson Sonsini
Goodrich & Rosati, Professional Corporation, is representing only the Company in this transaction. The Purchaser acknowledges that he or she has had the opportunity to review this Agreement, including all attachments hereto, and the
transactions contemplated by this Agreement with his or her own legal counsel, tax advisors and other advisors. The Purchaser is relying solely on his or her own counsel and advisors and not on any statements or representations of the Company or its
agents for legal or other advice with respect to this investment or the transactions contemplated by this Agreement. 

  
 Exhibit B-8 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 N.    Counterparts. This Agreement may be executed in one or
more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages shall be binding originals. 

(signature page follows) 

  
 Exhibit B-9 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 The parties represent that they have read this Agreement in its entirety, have had an opportunity
to obtain the advice of counsel prior to executing this Agreement and fully understand this Agreement. The Purchaser agrees to notify the Company of any change in his or her address below. 

 

					
	MAYO FOUNDATION FOR MEDICAL	 		 	
			
	EDUCATION AND RESEARCH	 		 	CENEXYS, INC.
			
	 /s/ Daniel D. Estes
	 		 	  

	Signature	 		 	Signature
			
	 Daniel D. Estes
	 		 	  

	Print Name	 		 	Print Name
			
		 		 	  

		 		 	Print Title
			
	Address:	 		 	
			
	 200 First Street SW
	 		 	
			
	 Rochester, MN 55905
	 		 	

  
 Exhibit B-10 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	i.	EXHIBIT A 

 INVESTMENT REPRESENTATION STATEMENT 

 

					
			
	PURCHASER	  	:	  	Mayo Foundation for Medical Education and Research
			
	COMPANY	  	:	  	Cenexys, Inc.
			
	SECURITY	  	:	  	Common Stock
			
	AMOUNT	  	:	  	2,000,000 shares
			
	DATE	  	:	  	[                    , 2013]

  
  

In connection with the purchase of the above-listed shares, I, the undersigned purchaser, represent to the Company as follows: 

1.    The Company may rely on these representations. I understand that the Company’s sale of the
shares to me has not been registered under the Securities Act of 1933, as amended (the “Securities Act”), because the Company believes, relying in part on my representations in this document, that an exemption from such
registration requirement is available for such sale. I understand that the availability of this exemption depends upon the representations I am making to the Company in this document being true and correct. 

2.    I am purchasing for investment. I am purchasing the shares solely for investment purposes, and
not for further distribution. My entire legal and beneficial ownership interest in the shares is being purchased and shall be held solely for my account, except to the extent I intend to hold the shares jointly with my spouse. I am not a party to,
and do not presently intend to enter into, any contract or other arrangement with any other person or entity involving the resale, transfer, grant of participation with respect to or other distribution of any of the shares. My investment intent is
not limited to my present intention to hold the shares for the minimum capital gains period specified under any applicable tax law, for a deferred sale, for a specified increase or decrease in the market price of the shares, or for any other fixed
period in the future. 
 3.    I can protect my own interests. I can properly evaluate the merits
and risks of an investment in the shares and can protect my own interests in this regard, whether by reason of my own business and financial expertise, the business and financial expertise of certain professional advisors unaffiliated with the
Company with whom I have consulted, or my preexisting business or personal relationship with the Company or any of its officers, directors or controlling persons. 

4.    I am informed about the Company. I am sufficiently aware of the Company’s business affairs
and financial condition to reach an informed and knowledgeable decision to acquire the shares. I have had opportunity to discuss the plans, operations and financial condition of the Company with its officers, directors or controlling persons, and
have received all information I deem appropriate for assessing the risk of an investment in the shares. 
 5.    I
recognize my economic risk. I realize that the purchase of the shares involves a high degree of risk, and that the Company’s future prospects are uncertain. I am able to hold the shares indefinitely if required, and am able to
bear the loss of my entire investment in the shares. 

  
 Exhibit B-11 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 6.    I know that the shares are restricted securities.
I understand that the shares are “restricted securities” in that the Company’s sale of the shares to me has not been registered under the Securities Act in reliance upon an exemption for
non-public offerings. In this regard, I also understand and agree that: 

A.    I must hold the shares indefinitely, unless any subsequent proposed resale by me is registered under the Securities
Act, or unless an exemption from registration is otherwise available (such as Rule 144); 
 B.    the Company is
under no obligation to register any subsequent proposed resale of the shares by me; and 
 C.    the certificate
evidencing the shares will be imprinted with a legend which prohibits the transfer of the shares unless such transfer is registered or such registration is not required in the opinion of counsel for the Company. 

7.    I am familiar with Rule 144. I am familiar with Rule 144 adopted under the Securities Act,
which in some circumstances permits limited public resales of “restricted securities” like the shares acquired from an issuer in a non-public offering. I understand that my ability to sell the shares
under Rule 144 in the future is uncertain, and may depend upon, among other things: (i) the availability of certain current public information about the Company; (ii) the resale occurring more than a specified period after my purchase and
full payment (within the meaning of Rule 144) for the shares; and (iii) if I am an affiliate of the Company (A) the sale being made in an unsolicited “broker’s transaction”, transactions directly with a market maker or
riskless principal transactions, as those terms are defined under the Securities Exchange Act of 1934, as amended, (B) the amount of shares being sold during any three-month period not exceeding the specified limitations stated in Rule 144,
and (C) timely filing of a notice of proposed sale on Form 144, if applicable. 
 8.    I know that
Rule 144 may never be available. I understand that the requirements of Rule 144 may never be met, and that the shares may never be saleable under the rule. I further understand that at the time I wish to sell the shares, there
may be no public market for the Company’s stock upon which to make such a sale, or the current public information requirements of Rule 144 may not be satisfied, either of which may preclude me from selling the shares under Rule 144
even if the relevant holding period had been satisfied. 
 9.    I know that I am subject to further restrictions
on resale. I understand that in the event Rule 144 is not available to me, any future proposed sale of any of the shares by me will not be possible without prior registration under the Securities Act, compliance with some other
registration exemption (which may or may not be available), or each of the following: (i) my written notice to the Company containing detailed information regarding the proposed sale, (ii) my providing an opinion of my counsel to
the effect that such sale will not require registration, and (iii) the Company notifying me in writing that its counsel concurs in such opinion. I understand that neither the Company nor its counsel is obligated to provide me with any such
opinion. I understand that although Rule 144 is not exclusive, the Staff of the SEC has stated that persons proposing to sell private placement securities other than in a registered offering or pursuant to Rule 144 will have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. 

  
 Exhibit B-12 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 10.    I know that I may have tax liability due to the uncertain value
of the shares. I understand that the board of directors believes its valuation of the shares represents a fair appraisal of their worth, but that it remains possible that, with the benefit of hindsight, the Internal Revenue Service
may successfully assert that the value of the shares on the date of my purchase is substantially greater than the Board’s appraisal. I understand that any additional value ascribed to the shares by such an IRS determination will constitute
ordinary income to me as of the purchase date, and that any additional taxes and interest due as a result will be my sole responsibility payable only by me, and that the Company need not and will not reimburse me for that tax liability. 

11.    Residence. The address of my principal residence is set forth on the signature page below.

 (signature page follows) 

  
 Exhibit B-13 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 By signing below, I acknowledge my agreement with each of the statements contained in this
Investment Representation Statement as of the date first set forth above, and my intent for the Company to rely on such statements in issuing the shares to me. 

 

	
	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
	
	 /s/ Daniel D. Estes

	Purchaser’s Signature
	
	 Daniel D. Estes

	Print Name
	
	 Assistant Treasurer

	Title

  

	
	Address of Purchaser’s principal address:
	
	 200 First Street SW

	
	 Rochester, MN 55905

  

	 	ii.	

  
 Exhibit B-14 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT C 

PROPRIETARY RESEACH TOOLS 
 [***]

  
 Exhibit C-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT D 

MATERIAL TRANSFER AGREEMENT 

MATERIAL TRANSFER AGREEMENT 

Mayo Foundation for Medical Education and Research 
  

					
	Dr.                                     
            	 	(Recipient Scientist)	 	DATE
	COMPANY NAME	 		 	
	ADDRESS	 		 	
	ADDRESS	 		 	

 Mayo Foundation for Medical Education and Research (MAYO) is pleased to be able to provide INSERT MATERIALS
HERE and any components thereof, which we shall refer to throughout this agreement as the “Material,” to you at COMPANY NAME (Company). MAYO is interested in supporting research using the Material and will provide you with samples of the
Material as long as you agree to certain conditions on your use of the Material. The conditions described below are necessary to insure that the Material is used solely for research and that MAYO’s interests in any possible commercialization of
the Material are protected. These conditions are: 
  

	1.	The Material is owned by MAYO and is provided under a license agreement effective as of          (“License”) between the parties. Upon termination of your research or
use of the Material and/or at the instructions of MAYO, you shall either return the Material to MAYO or destroy all unused portions of the Material. 

  

	2.	Use of the Material must be restricted to research experimentation in compliance with applicable laws and regulations. The Material must not be used in human subjects, in clinical trials, for diagnostic purposes
involving human subjects, or to make any derivatives or progeny, as applicable, thereof without the written consent of MAYO. 

  

	3.	 The Material must not be transferred to any other parties, other than researchers at your Company or
collaborators that are working on specific research projects on behalf of the Company (and transferred for the purpose of such collaboration) without first having obtained 

  
 Exhibit D-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	
a written agreement to the transfer from MAYO. No researchers working with you may use the Material unless they are aware of and agree to be bound by the terms of this agreement. Both parties
shall comply with all applicable laws and regulations, as amended from time to time, with respect to the collection, use, storage and disclosure of the Material and any related data, including without limitation, the Health Insurance Portability and
Accountability Act of 1996 (HIPAA) and its implementing regulations (45 C.F.R. et.seq.) 

  

	4.	Except to the extent prohibited by law, Company will assume all liability for damages which may arise from its use, storage or disposal of the Material. MAYO will not be liable to Company for any loss, claim or demand
made by Company or made against Company by any other party, due to or arising from the use of the Material by Company, except to the extent permitted by law when caused by the gross negligence or willful misconduct of MAYO. 

 

	5.	ANY MATERIAL DELIVERED PURSUANT TO THIS AGREEMENT IS UNDERSTOOD TO BE EXPERIMENTAL IN NATURE AND MAY HAVE HAZARDOUS PROPERTIES. ANY MATERIAL PROVIDED IS PROVIDED AS IS AND MAYO MAKES NO AND HEREBY DISCLAIMS ALL
REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK OR OTHER PROPRIETARY RIGHTS. 

  

	6.	Company agrees to provide appropriate acknowledgement of the source of the Material in all publications. 

  

	7.	Company agrees to pay $             in partial reimbursement of the costs of producing, maintaining and distributing the Material. 

 

	8.	Company will not use publicly for publicity, promotion, or otherwise, any logo, name, trade name, service mark, or trademark of MAYO or its Affiliates, including, but not limited to the terms “Mayo®,” “Mayo Clinic®,” and the triple shield Mayo logo, or any simulation, abbreviation, or adaptation of the same, or the name
of any MAYO employee or agent, without MAYO’s prior, written, express consent, other than provided in Section 6 above. MAYO may withhold such consent in MAYO’s absolute discretion. 

 

	9.	 This agreement, in conjunction with the license agreement, constitutes the final, complete and exclusive
agreement between the parties with respect to its subject matter and supercedes all past and contemporaneous agreements, promises, and understandings, whether oral or written, between the parties. This agreement shall be binding upon and inure to
the benefit of the parties, their heirs, legal representatives, successors and assigns. This agreement may not be amended or modified except by a writing signed by both parties and identified as an amendment to this agreement. Neither this agreement
nor any of the rights or obligations under the agreement may be assigned by Company without the written consent of MAYO. The 

  
 Exhibit D-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	
failure of MAYO to insist at any time upon the strict observance or performance of any of the provisions of this agreement, or to exercise any right or remedy as provided in this agreement, will
not impair any such right or remedy and will not be construed to be a waiver or relinquishment of the right or remedy. Execution of this agreement can be effected by photocopied, scanned or faxed signatures. 

If you agree to these conditions, please sign in the space provided below as the Recipient and have an authorized representative of your
Company sign where indicated. Return the agreement to Mayo Foundation for Medical Education and Research, Mayo Clinic Ventures, 200 First Street SW, Rochester, MN 55905. Upon receipt of the signed agreement, MAYO will provide the Material as
requested. 
 [SIGNATURES ON THE NEXT PAGE] 

  
 Exhibit D-3 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 

 

									
	By:	 	  
	 		 	Date:	 	  

		 	Daniel D. Estes, Assistant Treasurer	 		 		 	
	
	READ AND UNDERSTOOD BY THE RECIPIENT SCIENTIST:
				
	  
	 		 		 	  

				
	(Recipient Scientist Signature)*	 		 		 	(Recipient Scientist)
		 		 		 		 	
	ACCEPTED AND AGREED BY AUTHORIZED REPRESENTATIVE OF RECEIVING COMPANY
					
	By:	 	  
	 		 	Date:	 	  

				
	(Authorized Representative’s Signature)*	 		 		 	

  

			
	Printed Name and Title:	  	  

			
		
	Company:                	  	  

		
	Address:	  	  

		
	Phone No.:	  	  

  

	*	Please Note: The Recipient and the Authorized Representative cannot be the same. 

  
 Exhibit D-4 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]